study_id,theme,subtheme,summary,quote,quote_page,quote_section,location_context,confidence
Varghese2024-Multicountry-FALCON-2018-2020-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"High rates of multidrug resistance (MDR) were observed in SSI microorganisms, with 51.1% of isolates classified as MDR.",MDR was identified in 120 of 235 (51·1% [95% CI 44·5–57·6]) microorganisms.,7,Results,"Seven LMICs (Benin, Ghana, India, Mexico, Nigeria, Rwanda, South Africa)",high
Varghese2024-Multicountry-FALCON-2018-2020-01,drivers_amr,"inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors",Inappropriate use of antibiotics and poor infection prevention and control practices contribute to the emergence and spread of AMR.,the inappropriate use of antimicrobial drugs and poor infection prevention and control practices contribute to the emergence of and further spread of AMR,2,Introduction,Seven LMICs,high
Varghese2024-Multicountry-FALCON-2018-2020-01,prevention_control,"IPC programs, bundles, surveillance practices",Regular availability of infection control teams is associated with reduced MDR in SSI microorganisms.,"regular availability of infection control teams (0·32, 0·11–0·93) were associated with a significant reduction in MDR.",1,Summary,Seven LMICs,high
Varghese2024-Multicountry-FALCON-2018-2020-01,burden_incidence,"epidemiology of SSI (incidence, trends)",SSI incidence among abdominal surgery patients in LMICs was 22.0%.,"Overall, 1163 of 5284 patients (22·0% [95% CI 20·9–23·2]) at 50 hospitals were diagnosed with an SSI in the FALCON trial.",5,Results,Seven LMICs,high
Varghese2024-Multicountry-FALCON-2018-2020-01,microbiology_diagnostics,"lab capacity, methods, turnaround times","Testing capacity for microbiological analysis of SSI is low, with only 19.6% of SSI patients having a wound swab taken; turnaround time for results is often ≥48 hours.",228 of 1163 (19·6% [17·4–22·0]) had a wound swab taken.,5,Results,Seven LMICs,high
Varghese2024-Multicountry-FALCON-2018-2020-01,microbiology_diagnostics,"lab capacity, methods, turnaround times","Testing capacity for microbiological analysis of SSI is low, with only 19.6% of SSI patients having a wound swab taken; turnaround time for results is often ≥48 hours.",Turnaround time (from sending the wound swab to receiving the results) was reported to be 48 h or longer in 149 of 200 cases (74·5%) and 72 h or longer in 75 of 200 cases (37·5%).,7,Results,Seven LMICs,high
Abayneh2022-Ethiopia-MizanTepi-2021-01,burden_incidence,epidemiology of SSI,"The study found a high SSI rate of 12.6% among surgical patients, with higher rates in specific subgroups.","In this study, a total of 262 patients underwent surgical procedures, all of whom were followed up during the study. Of these, 33/262 (12.6%) developed SSIs within 30 days of the procedure.",4,Socio-Demographic Characteristics and Magnitude of SSIs,"Mizan-Tepi University Teaching Hospital, Ethiopia",high
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"All Gram-negative isolates were resistant to ampicillin, and high rates of multidrug resistance were observed among both Gram-negative and Gram-positive bacteria.","All (100.0%) Gram-negative isolates showed resistance toward ampicillin, and 91.7% of isolates were resistant toward amoxicillin-clavulanic acid.",7,Antimicrobial Resistance Profiles,"Mizan-Tepi University Teaching Hospital, Ethiopia",high
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"All Gram-negative isolates were resistant to ampicillin, and high rates of multidrug resistance were observed among both Gram-negative and Gram-positive bacteria.",Multidrug-resistance (MDR) towards three or more classes of antibiotics was 100.0%.,7,Antimicrobial Resistance Profiles,"Mizan-Tepi University Teaching Hospital, Ethiopia",high
Abayneh2022-Ethiopia-MizanTepi-2021-01,drivers_amr,"inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors",High resistance rates may be related to frequent and inappropriate use of antibiotics for therapeutic and prophylactic purposes.,This significantly higher resistance may be related to the frequent and inappropriate use of these antibiotics for therapeutic and prophylactic purposes in human infections.,10,Discussion,"Mizan-Tepi University Teaching Hospital, Ethiopia",moderate
Abayneh2022-Ethiopia-MizanTepi-2021-01,prevention_control,"IPC programs, bundles, surveillance practices","Periodic surveillance of bacterial profiles and antibiotic susceptibility testing, coupled with strict protocols for antibiotic administration and operative room regulations, is recommended.","Therefore, periodic surveillance of the bacterial profile and antibiotic susceptibility testing coupled with the implementation of a strict protocol for antibiotic administration and operative room regulations is important to minimize the burden of SSIs with resistant bacteria pathogens.",10,Conclusion,"Mizan-Tepi University Teaching Hospital, Ethiopia",high
Abayneh2022-Ethiopia-MizanTepi-2021-01,evidence_gaps,explicit gaps and research priorities,"The study did not use blood agar or molecular techniques, limiting detection of some pathogens and resistance genes.","In this study, blood agar medium was not used to detect SSI-causing pathogens, which could undermine the prevalence and types of isolated bacteria. Due to resource issues, molecular techniques to provide more information to indicate specific antibiotic resistance genes have not been performed.",10,Limitations of This Study,"Mizan-Tepi University Teaching Hospital, Ethiopia",high
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,other,"Most bacterial isolates from surgical wound infections were multidrug resistant, with overall MDR level at 80.8%.",The overall multi-drug resistance (MDR) level was at 80.8%. MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,5,Results,"Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia",high
Abosse2021-Ethiopia-FelegeHiwot-2019-01,drivers_amr,other,"Weak regulatory practice and inadequate bacteriological surveillance, along with free availability of antimicrobials, contribute to increased antimicrobial resistance.","The reported an increased MDR might be attributed by a number of factors including, over and misuse of antimicrobials in the study area where there is weak regulatory practice and inadequate bacteriological surveillance due to lack of routine antimicrobial susceptibility testing facilities. Most of the antimicrobials listed are freely available in local pharmacies and people could purchase and use them without prescription.",7,Discussion,"Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia",moderate
Abosse2021-Ethiopia-FelegeHiwot-2019-01,burden_incidence,other,Culture confirmed surgical wound infection prevalence was 69.7% among patients at the hospital.,The overall prevalence of culture confirmed SWI was 115 (69.7%),4,Results,"Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia",high
Ali2023-Ethiopia-DessieHospital-2016-01,burden_incidence,epidemiology of SSI,"The study found an average rate of surgical site infection (SSI) among patients undergoing surgery, with higher rates in general surgery compared to obstetrics/gynecology.","Clinically, 49 patients (14.5%) were diagnosed as developing surgical site infection, and wound swabs were taken for bacteriological study.",1,Abstract,"Dessie Comprehensive Specialized Hospital, Ethiopia",high
Ali2023-Ethiopia-DessieHospital-2016-01,burden_incidence,epidemiology of SSI,"The study found an average rate of surgical site infection (SSI) among patients undergoing surgery, with higher rates in general surgery compared to obstetrics/gynecology.","The rate of SSI was 16.8% and 9.2% in the general surgical ward and the obstetrics and gynecology ward, respectively.",4,The rate and distribution of SSI,"Dessie Comprehensive Specialized Hospital, Ethiopia",high
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"A high proportion of bacterial isolates from SSI cases were multidrug resistant, especially among Gram-negative organisms, with notable resistance to commonly used antibiotics.","Out of the total bacterial isolates, 38 (79.2%) isolates were found to be multidrug resistant, and the rate of multidrug resistant was higher among Gram-negative isolates.",1,Abstract,"Dessie Comprehensive Specialized Hospital, Ethiopia",high
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"A high proportion of bacterial isolates from SSI cases were multidrug resistant, especially among Gram-negative organisms, with notable resistance to commonly used antibiotics.","The highest resistance which is exhibited by Enterobacteriaceae isolates was for ampicillin (91.3%), followed by augmentin (87%), cotrimoxazole (82.6%), and ceftriaxone (78.3).",9,Discussion,"Dessie Comprehensive Specialized Hospital, Ethiopia",high
Ali2023-Ethiopia-DessieHospital-2016-01,drivers_amr,"determinants (inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors)","The high rate of multidrug resistance is attributed to antimicrobial drug overuse, overdosing, improper susceptibility testing, unethical drug promotion, self-medication, and prolonged hospitalization.","This coincides with the fact that the problem of MDR continues to grow, especially in developing countries, as a result of antimicrobial drug overuse, overdosing, drug prescription with an improper susceptibility test, unethical drug promotion, self-medication, and a long duration of hospitalization.",10,Discussion,"Dessie Comprehensive Specialized Hospital, Ethiopia",moderate
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,other,High rates of resistance to ampicillin and amoxycillin (>90%) were observed among both gram-positive and gram-negative bacteria isolates from SSI wounds.,Ampicillin and amoxycillin recorded resistance rates >90% against gram-positive and gram-negative bacteria.,2,Abstract,"Mama Lucy Kibaki Hospital, Nairobi, Kenya",high
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,other,Methicillin-resistant Staphylococcus aureus (MRSA) accounted for 65.4% of Staphylococcus species isolated from SSI wounds.,Methicillin-resistant S. aureus accounted for 65.4% (n=17) of the total Staphylococcus species.,2,Abstract,"Mama Lucy Kibaki Hospital, Nairobi, Kenya",high
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,burden_incidence,other,"A total of 58 cases of surgical site infection were observed over a 6-month period, with most isolates recovered from abdominal wounds.",A total of 58 cases of surgical site infection were observed at the facility between October 2018 and March 2019.,4,Socio-demographic data of patients,"Mama Lucy Kibaki Hospital, Nairobi, Kenya",high
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,burden_incidence,other,"A total of 58 cases of surgical site infection were observed over a 6-month period, with most isolates recovered from abdominal wounds.","Most of the bacteria were recovered from the abdomen 60.3% and the lower limbs 29.5%, with the arms and other body sites accounting for 3.8 and 6.4% of the total bacteria (Table 1).",4,Proportion of bacteria isolated from surgical wounds,"Mama Lucy Kibaki Hospital, Nairobi, Kenya",high
Billoro2019-Ethiopia-WUNEMMH-2017-01,burden_incidence,incidence,"SSI rate was 16.5% among surgical patients at WUNEMMH, higher than developed countries but similar to other African settings.","Out of 255 patients, 42(16.5%) patients developed SSIs.",3,Rate of SSI,"Ethiopia, WUNEMMH",high
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,resistance patterns,"Klebsiella pneumoniae was the most common SSI pathogen, with high sensitivity to ceftriaxone and ciprofloxacin; resistance to ampicillin, tetracycline, and erythromycin was noted.","Klebsiella pneumonia was found to be the most common for 60.0% of isolates followed by Staphylococcus aureus (17.8%), Escherichia colli (11.1%) and Pseudomonas aeruginosa (11.1%).",4,Etiological organisms for SSIs,"Ethiopia, WUNEMMH",high
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,resistance patterns,"Klebsiella pneumoniae was the most common SSI pathogen, with high sensitivity to ceftriaxone and ciprofloxacin; resistance to ampicillin, tetracycline, and erythromycin was noted.","Klebsiella species were 88.9% susceptible to ciprofloxacin, ceftriaxone, and Pseudomonas aeruginosa was 100% susceptible to both drugs.",4,Sensitivity of causative organisms,"Ethiopia, WUNEMMH",high
Billoro2019-Ethiopia-WUNEMMH-2017-01,drivers_amr,inappropriate use,Unnecessarily prolonged administration of antibiotics contributes to antimicrobial resistance; AMP for long periods should be avoided.,"Antimicrobial resistance is one of world problem, which results partly due to unnecessarily administration of antibiotic for long period so administration of surgical AMP for long time should be avoided.",6,Conclusion,"Ethiopia, WUNEMMH",moderate
Billoro2019-Ethiopia-WUNEMMH-2017-01,prevention_control,surveillance practices,Periodic surveillance and feedback to surgeons on SSI rates and associated factors are recommended to reduce SSI rates.,A surveillance system for SSI with feedback of proper data to surgeons and hospital authorities is highly recommended to reduce SSI rate in WUNEMMH.,7,Conclusion,"Ethiopia, WUNEMMH",moderate
Boru2025-Ethiopia-BuleHora-2023-01,burden_incidence,"epidemiology of SSI (incidence, trends)",The study found a high prevalence of SSIs (15.8%) among surgical patients at a tertiary hospital in Southern Ethiopia.,"In this study, the general prevalence of culture-confirmed SSIs was 15.8% (29/183) (95% CI, 10.9-22).",3,Prevalence of surgical site infections,"Bule Hora University Teaching Hospital, Ethiopia",high
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"A high proportion of isolates (43.9%) were multidrug-resistant, with S. aureus showing notable resistance to cefoxitin and penicillin.","Among the 41 isolates, 18 (43.9%) (95% CI, 43-45) were multidrug-resistant.",4,Multi-drug resistance pattern of bacteria,"Bule Hora University Teaching Hospital, Ethiopia",high
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"A high proportion of isolates (43.9%) were multidrug-resistant, with S. aureus showing notable resistance to cefoxitin and penicillin.",S. aureus: 57.1% resistant to cefoxitin (MRSA proxy); highest sensitivity to chloramphenicol.,4,Antimicrobial susceptibility patterns for Gram-positive isolates,"Bule Hora University Teaching Hospital, Ethiopia",high
Boru2025-Ethiopia-BuleHora-2023-01,drivers_amr,"determinants (inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors)","Self-medication and frequent, inappropriate use of antimicrobials may contribute to high resistance rates observed.",This high resistance may be due to self-medication practices and the frequent and inappropriate use of antimicrobial agents.,5,Discussion,"Bule Hora University Teaching Hospital, Ethiopia",moderate
Boru2025-Ethiopia-BuleHora-2023-01,outcomes_clinical,complications_other,"SSIs lead to increased mortality, morbidity, reoperation, prolonged hospital stays, and increased healthcare costs, especially with resistant organisms.","SSIs lead to increased mortality, morbidity, reoperation, prolonged hospital stays, loss of daily wages, and increased healthcare costs, all of which are considerably higher in cases involving antimicrobial-resistant organisms.",2,Background,"Bule Hora University Teaching Hospital, Ethiopia",moderate
Boru2025-Ethiopia-BuleHora-2023-01,prevention_control,"IPC programs, bundles, surveillance practices",The study recommends reviewing infection prevention practices and establishing a functional microbiology laboratory to control SSIs.,"This study recommends reviewing current infection prevention practices, establishing a functional microbiology laboratory, and limiting the use of certain antibiotics.",7,Conclusion and recommendation,"Bule Hora University Teaching Hospital, Ethiopia",moderate
Boru2025-Ethiopia-BuleHora-2023-01,evidence_gaps,explicit gaps and research priorities,"Future studies should include fungi and anaerobic bacteria, and a nationwide survey of SSIs and antimicrobial resistance is recommended.","Future studies should include fungi and anaerobic bacteria, and a nationwide survey of SSIs and antimicrobial resistance is recommended.",7,Conclusion and recommendation,Ethiopia,moderate
Burugu2022-Kenya-KenyattaNH-2022-01,burden_incidence,epidemiology of SSI,"SSI incidence among surgical patients at KNH was high, with 72.6% of samples showing bacterial growth.","Out of the 62 pus samples that were collected, bacterial isolates were recovered from seven in ten samples (n=45, 72.6%)",3,Results,"Kenya, Kenyatta National Hospital",high
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"High rates of resistance were observed among Gram-negative and Gram-positive isolates, including 91.7% ceftriaxone resistance in E. coli and 56.3% MRSA among S. aureus.",E. coli showed high resistance to ceftriaxone (91.7%).,3,Antimicrobial susceptibility patterns,"Kenya, Kenyatta National Hospital",high
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"High rates of resistance were observed among Gram-negative and Gram-positive isolates, including 91.7% ceftriaxone resistance in E. coli and 56.3% MRSA among S. aureus.",In cases of Staphylococcusaureus 56.3% of the isolates were found resistant to Methicillin (Oxacillin),4,Antibiotics susceptibility pattern of Gram-positive Isolates,"Kenya, Kenyatta National Hospital",high
Burugu2022-Kenya-KenyattaNH-2022-01,drivers_amr,inappropriate use,"Overuse and misuse of antibiotics, including prophylactic use, may contribute to high resistance rates observed.",Resistance to Ceftriaxone and Ampicillin could be explained by they having been used as prophylaxis preoperatively hence increasing their use in patients. Over-use of antibiotics has been shown to contributes to organisms developing resistance.,4,Discussion,"Kenya, Kenyatta National Hospital",moderate
Burugu2022-Kenya-KenyattaNH-2022-01,prevention_control,"IPC programs, bundles, surveillance practices",The study recommends infection control measures and surveillance to minimize the incidence of SSIs and spread of resistant isolates.,Control and prevention measures should be put into place as strategy to minimize the incidence of SSIs and the spread of resistance isolates.,2,Abstract,"Kenya, Kenyatta National Hospital",moderate
Burugu2022-Kenya-KenyattaNH-2022-01,prevention_control,"IPC programs, bundles, surveillance practices",The study recommends infection control measures and surveillance to minimize the incidence of SSIs and spread of resistant isolates.,There is need for continuous surveillance genotypic characterization of clinical isolates and their antimicrobial susceptibility patterns.,5,Future Scope,"Kenya, Kenyatta National Hospital",moderate
Burugu2022-Kenya-KenyattaNH-2022-01,evidence_gaps,explicit gaps and research priorities,The study highlights the need for national surveillance of antibiotic resistant organisms and further research including anaerobic cultures.,There is need to develop National surveillance of antibiotic resistant organisms.,5,Future Scope,"Kenya, Kenyatta National Hospital",moderate
Burugu2022-Kenya-KenyattaNH-2022-01,evidence_gaps,explicit gaps and research priorities,The study highlights the need for national surveillance of antibiotic resistant organisms and further research including anaerobic cultures.,Future studies should be extended to include cultures under anaerobic conditions to establish presence of other bacteria that require such environment for growth.,5,Future Scope,"Kenya, Kenyatta National Hospital",moderate
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,incidence_rates,"The SSI incidence rate for clean/clean-contaminated wounds was 7.0%, which authors noted as lower than rates in other Kenyan studies.",The SSI incidence rates (7.0%) observed in this study were relatively lower than the ones documented in other studies in Kenya.,1,ABSTRACT,"Aga Khan University Hospital, Nairobi, Kenya",high
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_distribution,"Staphylococcus aureus was the most frequently isolated pathogen from surgical site infections, accounting for 30.8% of isolates.","This study found out that the pathogens involved in SSI at the AKUHN included S. aureus (30.8%), Coagulase negative Staphylococcus (15.4%), Pseudomonas aeruginosa (10.4%), Kluyvera spp. (12.8%), E. coli (12.8%), Klebsiella species (12.8%), Serratia marcescens (2.6 %) and Enterobacter cloacae (2.6%).",5,DISCUSSION,"Aga Khan University Hospital, Nairobi, Kenya",high
Dinda2013-Kenya-AKUHNairobi-20082009-1,drivers_amr,patient_factors,Significant risk factors for developing an SSI were having a dirty wound (wound class IV) and a prolonged preoperative hospital stay of two or more days.,This study found out that wound class IV and preoperative stay ≥2 days were the risk factors associated with SSI at the hospital.,7,DISCUSSION,"Aga Khan University Hospital, Nairobi, Kenya",high
Dinda2013-Kenya-AKUHNairobi-20082009-1,microbiology_diagnostics,capacity_limitations,"The study's diagnostic approach was limited by the use of pus swabs, which are considered suboptimal specimens, and the absence of an anaerobic culture system.","Pus swabs are not ideal specimens for study of SSI according to CDC definitions; however, it was clinically not practical to obtain ideal specimens... The lack of anaerobic culture system was additional limitation.",7,DISCUSSION,"Aga Khan University Hospital, Nairobi, Kenya",high
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"High rates of multidrug resistance were observed among both Gram-positive and Gram-negative isolates from surgical site infections, including 70% MRSA and 100% resistance to ampicillin in E. coli.","All the Staphylococcus aureus isolates were resistant to penicillin. MRSA phenotype was observed in 70% of the isolates. Vancomycin, clindamycin, and erythromycin resistance were observed in 60%, 25%, and 25% of the isolates, respectively.",1,Background,"Asmara, Eritrea; Halibet and Orotta National Referral Hospitals",high
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"High rates of multidrug resistance were observed among both Gram-positive and Gram-negative isolates from surgical site infections, including 70% MRSA and 100% resistance to ampicillin in E. coli.",A high proportion (91%) of the Gram-negative bacteria were resistant to ampicillin and 100% of the Pseudomonas aeruginosa and Escherichia coli isolates were resistant to >5 of the tested antibiotics.,1,Background,"Asmara, Eritrea; Halibet and Orotta National Referral Hospitals",high
Garoy2021-Eritrea-AsmaraHospitals-2017-01,drivers_amr,"inappropriate use, IPC gaps, diagnostics delays, policy failures","The lack of infection control infrastructure and laboratory-based surveillance, as well as widespread use of cephalosporins for prophylaxis, are key drivers of AMR in Eritrea.","existing infection control practices in the country are largely rudimentary. To illustrate, the country has no infrastructure of trained infection-control professionals and lacks a laboratory-based surveillance and reporting system.",2,Background,"Eritrea, national referral hospitals",high
Garoy2021-Eritrea-AsmaraHospitals-2017-01,drivers_amr,"inappropriate use, IPC gaps, diagnostics delays, policy failures","The lack of infection control infrastructure and laboratory-based surveillance, as well as widespread use of cephalosporins for prophylaxis, are key drivers of AMR in Eritrea.",Another driver of the observed outcome is the extensive institutional use of cephalosporins in preoperative antibiotic prophylaxis (ceftriaxone and ampicillin are used extensively in this setting).,7,Discussion,"Eritrea, national referral hospitals",high
Garoy2021-Eritrea-AsmaraHospitals-2017-01,prevention_control,"IPC programs, bundles, surveillance practices","There is an urgent need for improved infection control policies, guidelines, and surveillance practices in Eritrea to address the high burden of MDR SSI.","Due to the high frequency of MDR isolates reported in this study, the development and implementation of suitable infection control policies and guidelines is imperative.",1,Background,"Eritrea, Halibet and Orotta National Referral Hospitals",high
Garoy2021-Eritrea-AsmaraHospitals-2017-01,prevention_control,"IPC programs, bundles, surveillance practices","There is an urgent need for improved infection control policies, guidelines, and surveillance practices in Eritrea to address the high burden of MDR SSI.","Much work is needed in Eritrea to formulate stricter policies and guidelines on infection control practices (decontamination of surfaces, antimicrobial surveillance, antibiotic stewardship, cohorting and decolonization of patients and healthcare workers, etc.).",9,Conclusion,"Eritrea, Halibet and Orotta National Referral Hospitals",high
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,prevention_control,workforce_training_education,"The intervention's success was partly attributed to a cultural and attitudinal change among staff, driven by formal and on-the-job training in IPC and AMS, which improved compliance with best practices.",A cultural and attitude change is essential to ensure that protocols for Infection Prevention and Control (IPC) and Antimicrobial Stewardship (AMS) are strictly followed,2,Background,"Dodoma Regional Referral Hospital, Tanzania",high
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,prevention_control,workforce_training_education,"The intervention's success was partly attributed to a cultural and attitudinal change among staff, driven by formal and on-the-job training in IPC and AMS, which improved compliance with best practices.",Formal education and on-job training of the health-care personnel were essential components of this intervention.,9,Risk factors for post-CS before and after the intervention,"Dodoma Regional Referral Hospital, Tanzania",high
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,drivers_amr,supply_chain_access,"Improving the supply chain for essential items like antibiotics, disinfectants, and disposables was a key component of the multifaceted intervention, suggesting that stockouts were a barrier to good practice.","strengthening the supply chain for antibiotics, disinfectants and operating room/laboratory disposables",2,Study procedures,"Dodoma Regional Referral Hospital, Tanzania",moderate
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,treatment_prophylaxis,inappropriate_use,"Prior to the intervention, there was routine, prolonged use of post-operative antibiotics (8-10 days) for caesarean sections, which was successfully replaced by appropriate single-dose pre-operative prophylaxis.","before the intervention, almost every woman received an antibiotic course lasting 8–10 days post-CS, irrespective of the presence of risk factors or signs/symptoms of infection.",3,Study procedures,"Dodoma Regional Referral Hospital, Tanzania",high
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,evidence_gaps,surveillance,"The authors state that the lack of detailed national surveillance data on MDRO prevalence is a major gap, highlighting the need for an efficient system to guide targeted public health interventions.",The lack of detailed data on MDROs prevalence all over the country highlights the need for building an efficient surveillance system in order to guide continuous targeted interventions.,9,Changes in the characteristics of the isolates after the intervention,Tanzania,high
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,burden_incidence,epidemiology of SSI,"SSI incidence was high (61.8%) among surgical patients, with most infections occurring before discharge.","In our study 126 (61.8%) patients have developed SSI, of which 73 (58%) were superficial incisional SSI and the rest were deep incisional SSI.",5,Occurrence of SSI,"Debre Berhan Comprehensive Specialized Hospital, Ethiopia",high
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,drivers_amr,inappropriate use,"Inappropriate selection, timing, and duration of SAP were common, with 77.9% of patients exposed to inappropriate prophylaxis.","In this study, 159 (77.9%) patients were exposed to inappropriate use of surgical antimicrobial prophylaxis as per different guidelines.",4,Utilization pattern and appropriateness of SAP,"Debre Berhan Comprehensive Specialized Hospital, Ethiopia",high
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,prevention_control,surveillance practices,Absence of culture and sensitivity testing and lack of antimicrobial stewardship programs were noted as barriers to effective SSI prevention.,The higher rate of SSI in the study area despite the institution of surgical antibiotic prophylaxis calls for the consideration of definitive laboratory diagnosis with culture and sensitivity study to come up with recommended antibiotics usage.,7,Conclusion,"Debre Berhan Comprehensive Specialized Hospital, Ethiopia",moderate
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,interventions_innovations,other,Recommendation to include clinical pharmacists in surgical ward teams to improve SAP utilization.,Including clinical pharmacists in the surgical ward service team should be also considered to ensure proper surgical antibiotic prophylaxis utilization.,7,Conclusion,"Debre Berhan Comprehensive Specialized Hospital, Ethiopia",moderate
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,evidence_gaps,explicit gaps and research priorities,No microbiological confirmation of SSI; lack of data on AMR patterns and absence of culture and sensitivity testing.,This means the pathogens responsible for surgical site infections may not have been covered by the prophylactic antibiotics or they may have developed resistance to these agents.,6,Discussion,"Debre Berhan Comprehensive Specialized Hospital, Ethiopia",high
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,incidence,"SSI incidence following limb amputation was 30%, higher than previous local studies.","The overall incidence of surgical site infections following limb amputations was found to be 30% in two referral hospitals in Mwanza, Tanzania.",5,Discussion,"Mwanza, Tanzania; Bugando Medical Centre and Sekou Toure Regional Referral Hospital",high
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,resistance patterns,"Gram-negative bacteria, especially E. coli, showed high resistance to third and fourth generation cephalosporins.",More than half of the Gram-negative isolates were resistant to third and fourth generations cephalosporins which were commonly used as prophylactic antibiotics in the study settings.,1,Abstract,"Mwanza, Tanzania; Bugando Medical Centre and Sekou Toure Regional Referral Hospital",high
Hamudu2025-Tanzania-BMC_SRHH-2024-01,drivers_amr,inappropriate use,Common use of cephalosporins for prophylaxis may contribute to resistance among Gram-negative pathogens.,More than half of the Gram-negative isolates were resistant to third and fourth generations cephalosporins which were commonly used as prophylactic antibiotics in the study settings.,1,Abstract,"Mwanza, Tanzania; Bugando Medical Centre and Sekou Toure Regional Referral Hospital",moderate
Hamudu2025-Tanzania-BMC_SRHH-2024-01,prevention_control,IPC programs,Study highlights need to improve infection prevention and control programs in hospitals.,This study has demonstrated an increased trend of SSI amongst patients who underwent limb amputation underscoring the need to improve infection prevention and control (IPC) programs in these hospitals.,7,Conclusion and recommendations,"Mwanza, Tanzania; Bugando Medical Centre and Sekou Toure Regional Referral Hospital",high
Hamudu2025-Tanzania-BMC_SRHH-2024-01,interventions_innovations,other,Recommendation to strengthen antimicrobial stewardship and IPC programs to control MDR Gram-negative bacteria.,The observed predominance of multi drug resistant (MDR) Gram negative bacteria causing SSI requires strengthening of antimicrobial stewardship and IPC programs in these hospitals and other hospitals in low- and middle-income countries to control emergence and spread of MDR Enterobacterales which have been classified by WHO as critical priority pathogens.,7,Conclusion and recommendations,"Mwanza, Tanzania; Bugando Medical Centre and Sekou Toure Regional Referral Hospital",high
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,resistance patterns,High rates of multidrug resistance (MDR) were observed among both Gram-positive and Gram-negative isolates from SSI patients.,Overall 86% of aerobic bacteria isolated were multidrug resistant (MDR) where 65.63% and 96.72% of Gram positive and Gram negative isolates were MDR respectively.,1,Abstract,"Mbarara Regional Referral Hospital, Uganda",high
Hope2019-Uganda-Mbarara-2015-01,drivers_amr,inappropriate use,Irrational use of antibiotics is identified as a major driver of antimicrobial resistance in the study setting.,This has majorly been attributed to increasing emergence of antimicrobial resistance due to irrational use of antibiotics.,1,Introduction,"Mbarara Regional Referral Hospital, Uganda",moderate
Hope2019-Uganda-Mbarara-2015-01,prevention_control,IPC programs,Strict adherence to good sanitation practice and periodic surveillance of SSIs are recommended to reduce spread of drug-resistant pathogens.,These findings necessitate judicious antibiotic use and calls for surveillance of SSIs periodically as well as strict adherence to good sanitation practice to reduce spread of drug-resistant pathogens.,1,Abstract,"Mbarara Regional Referral Hospital, Uganda",moderate
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,other,High prevalence of MRSA (63.5%) and MR-CNS (60%) among staphylococcal isolates from SSIs in Kinshasa.,"Out of 74 S. aureus and 15 CNS isolated, 47 (63.5%) and 9 (60%) were identified as MRSA and MR-CNS respectively.",1,Abstract,"Kinshasa, DRC, Provincial General Reference Hospital and Clinic of University of Kinshasa",high
Iyamba2014-DRC-Kinshasa-2013-01,drivers_amr,other,High MRSA and MR-CNS prevalence may be attributed to broad spectrum antibiotic use and long hospital stays.,The highest MRSA and MR-CNS prevalence observed in our study can be attributed to the high pressure use of broad spectrum antibiotics or to the long stay hospital.,3,Discussion,"Kinshasa, DRC",moderate
Iyamba2014-DRC-Kinshasa-2013-01,microbiology_diagnostics,other,Standard microbiological methods and CLSI disk diffusion were used for identification and susceptibility testing.,S. aureus and CNS strains were identified by standard microbiological methods and latex agglutination test (Pastorex Staph-Plus). The antibiotic susceptibility of all staphylococcal strains was carried out using disk-diffusion method.,1,Abstract,"Kinshasa, DRC, University of Kinshasa",high
Iyamba2014-DRC-Kinshasa-2013-01,policy_capacity,other,Antibiotic surveillance policy is lacking in DRC and recommended as a national priority.,MRSA and MR-CNS from SSIs to antibiotics remains unknown due to lack of antibiotic surveillance policies.,2,Introduction,DRC,high
Kachipedzu2024-Malawi-QECH-2023-1,burden_incidence,other,"The overall incidence of surgical site infections following caesarean section was 9.61% (20/208) over a 6-month period, which is considered high compared to developed countries.",The overall cumulative incidence of SSI recorded at QECH during the study period was 9.61% (20 cases out of 208).,1,Abstract,"QECH, Blantyre, Malawi",high
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,other,"Among 20 patients with SSI, 5 (25%) had antimicrobial resistance. Out of 10 cultured samples, 5 yielded bacterial growth, with Staphylococcus aureus (3 isolates) being the most common, showing resistance to clindamycin, erythromycin, gentamicin, and cefoxitin. Acinetobacter baumannii and Enterobacteriaceae were also isolated and showed resistance to multiple antibiotics.",5 (25%) out of 20 with SSIs had antimicrobial resistance following susceptibility testing.,1,Abstract,"QECH, Blantyre, Malawi",moderate
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,other,"Among 20 patients with SSI, 5 (25%) had antimicrobial resistance. Out of 10 cultured samples, 5 yielded bacterial growth, with Staphylococcus aureus (3 isolates) being the most common, showing resistance to clindamycin, erythromycin, gentamicin, and cefoxitin. Acinetobacter baumannii and Enterobacteriaceae were also isolated and showed resistance to multiple antibiotics.","The Staphylococcus aureus bacteria isolated were resistant to most antibiotics, including clindamycin, erythromycin, gentamicin, and cefoxitin.",5,Bacterial isolates and susceptibility pattern,"QECH, Blantyre, Malawi",moderate
Kachipedzu2024-Malawi-QECH-2023-1,drivers_amr,inappropriate_use,"A high proportion of patients (66.35%) received both pre-operative and post-operative antibiotics without a confirmed bacterial infection, contributing to unnecessary antibiotic use. The most common post-operative regimen was a combination of metronidazole and ceftriaxone, even in uncomplicated cases.",This study also revealed that 138 (66.35%) patients received both preop antibiotics (ceftriaxone) and post-CS antibiotics.,4,Antimicrobial use,"QECH, Blantyre, Malawi",high
Kachipedzu2024-Malawi-QECH-2023-1,drivers_amr,inappropriate_use,"A high proportion of patients (66.35%) received both pre-operative and post-operative antibiotics without a confirmed bacterial infection, contributing to unnecessary antibiotic use. The most common post-operative regimen was a combination of metronidazole and ceftriaxone, even in uncomplicated cases.",No patient had a known infection or specific bacterial organism isolated in the current study at the time these antibiotics were prescribed and administered which may increase the risk for antimicrobial resistance spread.,4,Antimicrobial use,"QECH, Blantyre, Malawi",high
Kachipedzu2024-Malawi-QECH-2023-1,policy_capacity,other,The study highlights a need to establish formal antimicrobial stewardship programs and routine surveillance for SSIs at the hospital to address the high SSI rate and inappropriate antibiotic use.,"Therefore, due to increased number of SSIs following CS with relative emergence of AMR ensure intensive infection prevention and control practices, establishing AMS program and routine surveillance of SSIs at QECH.",1,Conclusion,"QECH, Blantyre, Malawi",high
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,epidemiology of SSI,SSI prevalence was high (19.6%) among surgical patients at a tertiary hospital in Ethiopia.,The present study showed that 19.6% (95% CI: 18–21.1) of patients developed SSIs.,5,Prevalence of Surgical Site Infections,"Finote Selam General Hospital, Ethiopia",high
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,drivers_amr,"inappropriate use, IPC gaps","Inappropriate timing and duration of prophylactic antibiotics, and lack of adequate infection control systems, were identified as drivers of SSI.","The higher prevalence of SSI in our setting could be due to the lack of adequate infection control systems, poor practices, and inappropriate use of antibiotics.",6,Discussion,"Finote Selam General Hospital, Ethiopia",moderate
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,prevention_control,"IPC programs, bundles, surveillance practices",Adherence to recommended guidelines for SAP timing and duration is necessary to reduce SSI risk.,Healthcare professionals should consider the above risk factors while they are undergoing surgical procedures. They should also adhere to the recommended treatment guideline to prescribe appropriate prophylactic surgical antibiotics.,8,Conclusion,"Finote Selam General Hospital, Ethiopia",moderate
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,treatment_prophylaxis,"prophylaxis regimens, therapeutic choices, adherence",Ceftriaxone and metronidazole were the most frequently used prophylactic antibiotics; 7.2% of regimens were inappropriate.,"Ceftriaxone and metronidazole (45.4%), and ceftriaxone (33.3%) were the most frequently used prophylactic antibiotics. Of the prescribed antibiotics, 7.2% were inappropriate.",6,Prevalence of Surgical Site Infections,"Finote Selam General Hospital, Ethiopia",high
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,evidence_gaps,explicit gaps and research priorities,There is a paucity of data on SSI and antibiotic use in Northwest Ethiopia.,"Although several studies have been conducted on SSIs, with significant variations in different regions, there was a paucity of data in the Northwest part of Ethiopia.",3,Introduction,Northwest Ethiopia,high
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,epidemiology of SSI,"Wound infection is a significant clinical challenge in Buea hospitals, with a high prevalence (79.7%) among hospitalized patients.",Wound infection is a significant clinical challenge in hospitals in developing countries where proper healthcare delivery is hampered by limited resources.,1,Abstract,"Buea, Cameroon",high
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,epidemiology of SSI,"Wound infection is a significant clinical challenge in Buea hospitals, with a high prevalence (79.7%) among hospitalized patients.",Bacteria were isolated from 169 (79.7%) specimens.,3,Results,"Buea, Cameroon",high
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"Predominant isolates (S. aureus, P. aeruginosa, K. pneumoniae) exhibited high rates of multidrug resistance, with all isolates resistant to oxacillin and susceptible to fluoroquinolones.","Staphylococcus aureus, Pseudomonas aeruginosa and Klebsiella pneumoniae, the predominant isolates in all wound types exhibited a high preponderance of multidrug resistant strains.",1,Abstract,"Buea, Cameroon",high
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"Predominant isolates (S. aureus, P. aeruginosa, K. pneumoniae) exhibited high rates of multidrug resistance, with all isolates resistant to oxacillin and susceptible to fluoroquinolones.",All isolates (100%) were susceptible to ofloxacin and pefloxacin but resistant to oxacillin.,3,Results,"Buea, Cameroon",high
Akoachere2014-Cameroon-Buea-201010201103-01,drivers_amr,"inappropriate use, IPC gaps, supply chain, workforce","High rate of infection attributed to lack of constant water supply, breakdown of sterilization equipment, and widespread empiric use and misuse of antibiotics.",High rate of infection was attributed to lack of constant water supply and breakdown of sterilization equipment during the study period.,1,Abstract,"Buea, Cameroon",high
Akoachere2014-Cameroon-Buea-201010201103-01,drivers_amr,"inappropriate use, IPC gaps, supply chain, workforce","High rate of infection attributed to lack of constant water supply, breakdown of sterilization equipment, and widespread empiric use and misuse of antibiotics.",These drugs are relatively cheap and are sold by unauthorized persons and without prescriptions. Their high level of misuse accounts for the high levels resistance observed.,5,Discussion,"Buea, Cameroon",high
Akoachere2014-Cameroon-Buea-201010201103-01,prevention_control,"IPC programs, surveillance practices","Findings reiterate the need to strengthen infection control and drug dispensing policies, and greater collaboration between microbiologists and medical practitioners.","Findings reiterate the need to strengthen infection control and drug dispensing policies, and greater collaboration between microbiologists and medical practioners to stem the spread of resistant bacteria.",1,Abstract,"Buea, Cameroon",high
Akoachere2014-Cameroon-Buea-201010201103-01,evidence_gaps,explicit gaps and research priorities,No anaerobic cultures performed; minimum inhibitory concentrations not determined; limitation in detection of polymicrobial and anaerobic infections.,No anaerobic cultures performed; limitation noted.,4,Discussion,"Buea, Cameroon",high
Akoachere2014-Cameroon-Buea-201010201103-01,evidence_gaps,explicit gaps and research priorities,No anaerobic cultures performed; minimum inhibitory concentrations not determined; limitation in detection of polymicrobial and anaerobic infections.,We did not determine the minimum inhibitory concentrations of potent antibiotics. This constituted another limitation to our study.,4,Discussion,"Buea, Cameroon",high
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"High rates of resistance to commonly used antibiotics were observed among Gram-negative and Gram-positive isolates, including 100% penicillin resistance in S. aureus and >70% resistance to ampicillin and cefazolin in Proteus and Klebsiella spp.","All Staphylococcus aureus tested were resistant to penicillin (n = 22, 100%) and susceptible to vancomycin. Significant resistance to cephalosporins such as cefazolin (n = 62, 72.9%), ceftriaxone (n = 44, 51.8%) and ceftazidime (n = 40, 37.4%) was observed in Gram-negative bacteria, as well as resistance to cefoxitin (n = 6, 27.3%) in S. aureus.",1,Abstract,"KCMC, Moshi, Tanzania",high
Kumburu2017-Tanzania-KCMC-2013-2015-01,drivers_amr,inappropriate use,"A majority of patients (71.9%) had received antibiotics prior to admission, with common use of ceftriaxone, metronidazole, and cloxacillin, suggesting widespread empirical and possibly inappropriate antibiotic use.","About three-quarters of the patients (n = 412, 71.9%) had a history of antibiotic/antimicrobial treatment before arriving to the hospital (Table 1). Drugs that were commonly used were ceftriaxone (n = 173, 46.2%), metronidazole (n = 147, 39.4%), cloxacillin (n = 64, 17.1%), ciprofloxacin (n = 25, 6.6%) and co-trimoxazole (n = 21, 5.5%).",4,Pattern of resistance to antimicrobial agents,"KCMC, Moshi, Tanzania",high
Kumburu2017-Tanzania-KCMC-2013-2015-01,policy_capacity,surveillance,"The study highlights the need for regular generation and reporting of data on aetiological agents and antimicrobial susceptibility, with recommendations for sentinel sites and a central organising body.",Sentinel sites (hospitals) across the country (and region) should report on a representative subset of bacterial species and their susceptibility to drugs at least annually. A central organising body should collate the data and report to relevant national and international stakeholders.,1,Abstract,Tanzania (national recommendation),high
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,High rates of antimicrobial resistance were found across gram-negative and gram-positive species towards the most common empiric antibiotics.,"With 98% resistance towards ceftriaxone and 51% resistance towards gentamicin, a large proportion of all pathogens demonstrated resistance, or were intrinsically resistant, to the most commonly used empiric antibiotics.",7,3.2 Type and prevalence of pathogens and resistance patterns,"Mulago National Referral Hospital, Kampala, Uganda",high
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,drivers_amr,"inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors","Empirical antibiotic treatment is commonly based on clinical judgement without knowledge of pathogen and resistance patterns, and self-prescription is prevalent.","Empirical antibiotic treatment on the ward was commonly based on clinical judgement without knowledge of pathogen and resistance patterns. The ability to perform microbial testing was limited, since it is an unaffordable out-of-pocket expense for most patients in this setting.",9,4. Discussion,"Mulago National Referral Hospital, Kampala, Uganda",high
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,drivers_amr,"inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors","Empirical antibiotic treatment is commonly based on clinical judgement without knowledge of pathogen and resistance patterns, and self-prescription is prevalent.","Over 80% of them bought antimicrobials directly in community drug shops or pharmacies without a medical prescription, which underlines the high prevalence of self-prescription in our sample, similar to the available literature [19,20].",9,4. Discussion,"Mulago National Referral Hospital, Kampala, Uganda",high
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,prevention_control,"IPC programs, bundles, surveillance practices","Nosocomial infections are common, possibly due to long hospital stays and suboptimal infection prevention and control.",Nosocomial infections might be more common in Uganda as hospital stays tend to be long due to treatment delays and IPC is often not optimal [44].,9,4. Discussion,Uganda,moderate
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,interventions_innovations,evaluated interventions and novel approaches,Routine microbial diagnostics and AST enabled targeted therapy and diversification of treatment options.,The use of AST in our study enabled the diversification of treatment options and guided clinical decision-making.,9,4. Discussion,"Mulago National Referral Hospital, Kampala, Uganda",high
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,policy_capacity,"national/regional capacity, GLASS, stewardship policy","Uganda has a National Action Plan on AMR and participates in GLASS, but lacks routine lab-based surveillance and comprehensive stewardship programs.","Despite being the first African country to implement a structured national AMR surveillance program in alignment with the WHO Global Antimicrobial Resistance Surveillance System (GLASS) in 2015 [8], the magnitude of AMR in Uganda remains largely unknown due to a lack of access to microbiological diagnostics.",2,1.1 Antimicrobial resistance in Uganda,Uganda,high
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"A high proportion (63%) of isolates causing SSIs were multidrug resistant, with 90% resistant to more than four classes of antibiotics.","A high proportion (63%) of the isolates causing SSIs in this tertiary hospital were MDR, of which (90%) were resistant to more than four classes of antibiotics.",1,Abstract,"Muhimbili National Hospital, Tanzania",high
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,drivers_amr,inappropriate use,"High levels of antibiotic resistance may be attributed to inappropriate use of antimicrobial agents, affecting both cost and efficacy.","The very high levels of antibiotics resistance seen in this study could be attributed, at least in part, to inappropriate use of antimicrobial agents affects both the cost and efficacy, thus favoring the emergence of resistant bacteria.",6,Discussion,"Muhimbili National Hospital, Tanzania",moderate
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,prevention_control,surveillance practices,The study highlights the need for urgent revision of perioperative antimicrobial prophylaxis and standardized antibiotic management.,"There is a very urgent need of revising the perioperative antimicrobial prophylaxis at this national referral Hospital to provide clinicians with standardized approach to the rational, safe and effective use of antibiotics management of SSI.",6,Conclusion,"Muhimbili National Hospital, Tanzania",high
Mengesha2014-Ethiopia-Ayder-2012-1,burden_incidence,"epidemiology of SSI (incidence, trends)",High prevalence of post-surgical wound infection (75%) observed in Ayder Teaching and Referral Hospital.,Prevalence of was Post-operative wound infections rate in this current study was 75%,1,Abstract,"Ethiopia, Ayder Teaching and Referral Hospital",high
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"High rates of multidrug resistance (82.92%) among isolates, with most Gram-negative and Gram-positive bacteria sensitive only to gentamicin and vancomycin, respectively.",multi drug resistance was seen in 102/123(82.92%) of the isolates leaving clinicians with few choices of drugs for the treatment of post surgical wound infected patients.,1,Abstract,"Ethiopia, Ayder Teaching and Referral Hospital",high
Mengesha2014-Ethiopia-Ayder-2012-1,drivers_amr,inappropriate use,Indiscriminate use and easy availability of antibiotics may contribute to high resistance rates.,This remarkably higher resistance may be due to their easily availability and indiscriminate use of the drugs without proper prescription.,5,Discussion,"Ethiopia, Ayder Teaching and Referral Hospital",moderate
Mengesha2014-Ethiopia-Ayder-2012-1,prevention_control,surveillance practices,Periodic surveillance of bacteria and antibiotic susceptibility is recommended to prevent further emergence and spread of resistant pathogens.,"Therefore, periodic surveillance of bacteria and antibiotic susceptibility is important to prevent further emergence and spread of resistant bacteria pathogens.",6,Conclusion,"Ethiopia, Ayder Teaching and Referral Hospital",high
Mengesha2014-Ethiopia-Ayder-2012-1,evidence_gaps,explicit gaps and research priorities,Lack of data on anaerobic bacteria and fungi in post-surgical wound infections is a limitation.,"The study did not isolate strict anaerobes bacteria and fungi, which could have increased the number of bacterial isolates reported as negative cultures.",5,Limitation,"Ethiopia, Ayder Teaching and Referral Hospital",high
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,other,"High rates of antimicrobial resistance were observed among SSI isolates, especially to ceftriaxone and other commonly used antibiotics.","The Gram-negative pathogens showed high resistance toward Cefepime (87.88%), ceftriaxone (78.79%), Cefuroxime (63.63%), cotrimoxazole (54.55%), ciprofloxacin (60.60%), and ampicillin (60.60%).",5,Antibiotic susceptibility pattern of SSI isolates,"Jimma Medical Center, Ethiopia",high
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,burden_incidence,other,SSI incidence was high (21.1%) among surgical patients at Jimma Medical Center.,"From a cohort of 251 patients who underwent surgery at Jimma Medical Center, 53 (21.1%) of them developed surgical site infections.",4,Incidence of SSI,"Jimma Medical Center, Ethiopia",high
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,drivers_amr,other,"Indiscriminate use of antibiotics, especially ceftriaxone, may contribute to high resistance rates.",This remarkably higher resistance might be the indiscriminate use of ceftriaxone as prophylaxis to all who underwent surgery in our hospital.,8,Discussion,"Jimma Medical Center, Ethiopia",moderate
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,prevention_control,other,Routine microbial analysis and proper infection prevention practices are recommended to address high SSI and AMR rates.,"As there is high antibiotic resistance observed in the current study, it is necessary for routine microbial analysis of samples and their antibiogram. In addition, we recommend proper infection prevention practices to break the disease transmission cycle.",8,Conclusion,"Jimma Medical Center, Ethiopia",high
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,incidence,"SSI incidence rate at CHUK was 10.9%, comparable to other developing countries.",The overall incidence of SSI after surgery was 10.2% (34/294)...,3,Incidence rate of surgical site infections,"Rwanda, CHUK",high
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,amr_prevalence,resistance patterns,"High resistance rates to commonly used antibiotics (amoxicillin-clavulanate, gentamicin, ciprofloxacin, ceftriaxone) among SSI isolates; amikacin and imipenem remained effective.","The pathogens revealed different levels of antibiotic resistance; amoxy-clavilinic acid (98.8%), gentamicin (92.6%), ciprofloxacin (78.1%) and ceftriaxone (53.3%).",1,Abstract,"Rwanda, CHUK",high
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,drivers_amr,inappropriate use,High resistance may be due to easy availability and inappropriate use of antibiotics in hospitals.,This remarkably higher resistance may be due to their easily availability and inappropriate use of the drugs in our hospitals.,7,Discussion,"Rwanda, CHUK",moderate
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,prevention_control,surveillance practices,"Periodic surveillance of bacteria and antibiotic susceptibility, coupled with strict protocols for antibiotic administration and operative room regulations, are recommended.",Periodic surveillance of bacteria and antibiotic susceptibility coupled with the implementation of strict protocol for antibiotic administration and operative room regulations are important to minimize the burden of SSI with resistant bacteria pathogens.,1,Abstract,"Rwanda, CHUK",high
DeNardo2016-Tanzania-Dodoma-2013-1,burden_incidence,other,"The study documented an extremely high incidence of post-caesarean section SSI at 48.2%, which is substantially higher than other reports from the same country, indicating a significant local burden of infection.","The detected incidence rate of post-CS SSI was extremely high, at 48.2%. A recent report from Tanzania documented a more than four-fold lower incidence of post-CS SSI compared with our study (10.9% vs 48.2%).",3,Discussion,"Dodoma Regional Referral Hospital, Tanzania",high
DeNardo2016-Tanzania-Dodoma-2013-1,amr_prevalence,other,"A very high MRSA prevalence of 79% among S. aureus isolates from SSIs was found, suggesting significant healthcare-associated transmission and a high burden of resistant pathogens.",The MRSA prevalence rate (79%) also seems to suggest healthcare-associated infections...,3,Discussion,"Dodoma Regional Referral Hospital, Tanzania",high
DeNardo2016-Tanzania-Dodoma-2013-1,drivers_amr,inappropriate_use,"Inappropriate antibiotic use, particularly the administration of prophylaxis post-operatively rather than pre-incision and the use of third-generation cephalosporins, is cited as a likely driver of high infection and resistance rates.","...inappropriate use of antibiotics, particularly third-generation cephalosporins.",3,Discussion,"Dodoma Regional Referral Hospital, Tanzania",high
DeNardo2016-Tanzania-Dodoma-2013-1,drivers_amr,inappropriate_use,"Inappropriate antibiotic use, particularly the administration of prophylaxis post-operatively rather than pre-incision and the use of third-generation cephalosporins, is cited as a likely driver of high infection and resistance rates.",no consistent protocol for the administration of antibiotic prophylaxis is available and usually antimicrobials are administered after the operation...,3,Discussion,"Dodoma Regional Referral Hospital, Tanzania",high
DeNardo2016-Tanzania-Dodoma-2013-1,drivers_amr,IPC_gaps,Likely contamination in the operating theatre and overcrowding in wards are highlighted as potential drivers of nosocomial infections.,...probable contamination in the theatre during the operations.,3,Discussion,"Dodoma Regional Referral Hospital, Tanzania",high
DeNardo2016-Tanzania-Dodoma-2013-1,drivers_amr,IPC_gaps,Likely contamination in the operating theatre and overcrowding in wards are highlighted as potential drivers of nosocomial infections.,The overcrowding of labour rooms and post-delivery ward...need to be addressed to decrease the occurrence of nosocomial infections...,3,Discussion,"Dodoma Regional Referral Hospital, Tanzania",high
DeNardo2016-Tanzania-Dodoma-2013-1,drivers_amr,workforce,"Surgical procedures performed by less experienced junior doctors were associated with a higher risk of SSI, indicating that staff training and supervision are important determinants of surgical outcomes.",Univariate analysis suggested that surgical procedures performed by interns were associated with a higher risk of SSI compared with those performed by senior doctors...,3,Discussion,"Dodoma Regional Referral Hospital, Tanzania",high
DeNardo2016-Tanzania-Dodoma-2013-1,policy_capacity,stewardship_policy,"The facility lacks both antimicrobial stewardship programs and consistent protocols for surgical antibiotic prophylaxis, highlighting a need to review and implement national and local guidelines.","...the lack of antimicrobial stewardship, need to be addressed to decrease the occurrence of nosocomial infections and the burden of resistant bacteria.",3,Discussion,"Dodoma Regional Referral Hospital, Tanzania",high
DeNardo2016-Tanzania-Dodoma-2013-1,policy_capacity,stewardship_policy,"The facility lacks both antimicrobial stewardship programs and consistent protocols for surgical antibiotic prophylaxis, highlighting a need to review and implement national and local guidelines.",This ﬁnding may highlight a substantial need to review national guidelines and internal operative protocols on the management of pregnant women undergoing CS.,3,Discussion,"Dodoma Regional Referral Hospital, Tanzania",high
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,burden_incidence,other,"The overall SSI rate after emergency cesarean section in this rural Rwandan hospital was 4%, lower than expected and similar to rates in middle-income countries.","The overall prevalence of SSI in our population was 4.00%, which was surprisingly low compared to the baseline assumptions, which were calculated based on the literature available from other African countries.",6,Incidence of surgical site infection in both groups,"Ruhengeri Hospital, Rwanda",high
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,prevention_control,other,Rigorous infection control measures and proper timing of prophylactic antibiotics may have contributed to the low SSI rate observed.,The overall observed low rate SSI in our Study might have been a result of some good practices in infections prevention practices which were systematic in Ruhengeri Hospital. These included adequate timing of prophylactic antibiotics as all women were given the first doses before they enter the operating room ensuring antibiotics are given before skin incision as recommended.,7,Discussion,"Ruhengeri Hospital, Rwanda",high
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,drivers_amr,other,Provider preference for extended antibiotic regimens and workload limited enrollment and adherence to protocol.,Some of the challenges which contributed to the limitation of our study included providers related factors; some of the healthcare providers preferred to stick on their routine practice of using extended dose of antibiotics or a packed workload prevented them from enrolling many women who were eligible to participate in the study.,7,Discussion,"Ruhengeri Hospital, Rwanda",moderate
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"High rates of ESBL (46%) and carbapenemase (15%) producing Enterobacteriaceae were found among SSI suspects, with predominant resistance to cefepime, ceftriaxone, ceftazidime, and amoxicillin-clavulanic acid.","Of 69 Enterobacteriaceae isolates, 66.6 % (46/69) were positive for ESBL production, and 21.7 (15/69) were positive for carbapenemase-producing Enterobacteriaceae.",1,Result,"Southern Ethiopia, Wolaita Sodo Comprehensive Specialized Hospital and Sodo Christian General Hospital",high
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"High rates of ESBL (46%) and carbapenemase (15%) producing Enterobacteriaceae were found among SSI suspects, with predominant resistance to cefepime, ceftriaxone, ceftazidime, and amoxicillin-clavulanic acid.","The majority of Enterobacteriaceae isolates showed sensitivity to meropenem (72.1%); however revealed 63.9% and 70.5% were resistant to gentamicin and ciprofloxacin, respectively.",1,Result,"Southern Ethiopia, Wolaita Sodo Comprehensive Specialized Hospital and Sodo Christian General Hospital",high
Odoko2024-Ethiopia-SodoHospitals-2022-01,drivers_amr,"inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors","Overuse of antibiotics, self-medication, prescribing without susceptibility testing, and prolonged hospital stays are contributing factors to ESBL and CPE prevalence.","The issue of ESBL in developing countries has been made severe by the overuse of antibiotics, overdosing, self-medication, prescribing medications without conducting the proper susceptibility testing, and extended hospital stays.",3,Introduction,Southern Ethiopia,moderate
Odoko2024-Ethiopia-SodoHospitals-2022-01,prevention_control,"IPC programs, bundles, surveillance practices","Advancements in infection prevention and control practices have occurred, but SSIs remain a major cause of prolonged hospital stays, morbidity, and mortality.","While there have been advancements in infection prevention and control practices, such as better ventilation of surgical sites, surgical techniques, barriers, and the availability of antimicrobials or antibiotics used for prophylaxis, surgical site infections (SSIs) still account for a major cause of prolonged hospital stays, morbidity, and mortality.",2,Introduction,Southern Ethiopia,moderate
Odoko2024-Ethiopia-SodoHospitals-2022-01,evidence_gaps,explicit gaps and research priorities,"Research on ESBL and CPE for SSI is lacking in developing nations like Ethiopia, especially in southern regions.","Yet, research on ESBL and CPE for SSI is lacking in developing nations like Ethiopia, and no study has previously examined the prevalence of ESBL and CPE with SSI in the southern Ethiopian region of Wolaita.",3,Introduction,Southern Ethiopia,high
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"High rates of multidrug resistance were observed among MRSA isolates from surgical site infections, with resistance to most commonly available antibiotics except vancomycin and clindamycin (though inducible resistance was common).","Resistance rates of MRSA were 88.2% for trimethoprim-sulfamethoxazole, 88.2% for erythromycin, 58.8% for gentamycin, 70.6% for ciprofloxacin, and 88.2% for chloramphenicol. All isolates were found to be sensitive to vancomycin and clindamycin though the D-test was found to be positive in 82.4% of the isolates.",1,Abstract,"Mulago Hospital, Kampala, Uganda",high
Ojulong2009-Uganda-Mulago-2007-01,drivers_amr,"inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors",The high prevalence of multidrug resistant MRSA is attributed to the use of broad-spectrum antibiotics and possible clonal expansion and drug pressure in the community.,"Gentamycin, which was proposed to be an alternative therapy to MRSA infection, was found to be still better in this part of the world (52.6%). This is perhaps due to the different clonal expansion and drug pressure in the community.",3,Discussion,"Mulago Hospital, Kampala, Uganda",moderate
Ojulong2009-Uganda-Mulago-2007-01,drivers_amr,"inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors",The high prevalence of multidrug resistant MRSA is attributed to the use of broad-spectrum antibiotics and possible clonal expansion and drug pressure in the community.,The use of broad-spectrum antibiotics for treating infections also increases the rate of MRSA and other resistant bacteria.,4,Discussion,"Mulago Hospital, Kampala, Uganda",moderate
Ojulong2009-Uganda-Mulago-2007-01,microbiology_diagnostics,"lab capacity, methods, turnaround times","MRSA identification was confirmed by standard methods and PCR, with susceptibility testing performed by disc diffusion and agar screen methods according to CLSI standards.",S. aurues isolates were identified using standard procedures and tested for oxacillin resistance according to methods of the National Committee for Clinical Laboratory Standards.,1,Abstract,"Mulago Hospital, Kampala, Uganda",high
Ojulong2009-Uganda-Mulago-2007-01,microbiology_diagnostics,"lab capacity, methods, turnaround times","MRSA identification was confirmed by standard methods and PCR, with susceptibility testing performed by disc diffusion and agar screen methods according to CLSI standards.","Identification of S. aureus was confirmed by standard methods and susceptibility testing was performed by disc diffusion on Mueller-Hinton agar (Difco, USA) with 24-h incubation at 35°C. Interpretation criteria were those of the National Committee for Clinical Laboratory Standards (2003). Resistance to oxacillin was confirmed by agar screen method using an agar plate containing 6 µg/ml of oxacillin and Mueller-Hinton agar supplemented with NaCl (4% w/v; 0.68 mol/L).",2,Laboratory protocol,"Mulago Hospital, Kampala, Uganda",high
Ojulong2009-Uganda-Mulago-2007-01,prevention_control,"IPC programs, bundles, surveillance practices",Hand hygiene and avoidance of transmission by caregivers are recognized as effective methods for controlling MRSA spread.,The first and the most effective way among these are to avoid transmission through hand contamination by the person responsible for caring the infected patients.,4,Discussion,"Mulago Hospital, Kampala, Uganda",moderate
Ojulong2009-Uganda-Mulago-2007-01,evidence_gaps,explicit gaps and research priorities,A larger study is recommended to determine antibiotic susceptibility of MRSA in various hospitals in the East African region.,A further large study with a large sample should be carried out to find antibiotic susceptibility of MRSA in various hospitals in the East African region.,4,Discussion,East African region,high
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"MRSA is highly prevalent (31.5%) among S. aureus isolates from surgical site infections in Mulago Hospital, Uganda.",Seventeen (31.5%) of the 54 isolates were confirmed as MRSA by PCR.,4,Abstract,"Mulago National Referral Hospital, Kampala, Uganda",high
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"MRSA is highly prevalent (31.5%) among S. aureus isolates from surgical site infections in Mulago Hospital, Uganda.","MRSA is highly (31.5%) prevalent among populations of S. aureus isolated from surgical site infections in Mulago National Referral Hospital, Kampala Uganda.",12,Conclusion,"Mulago National Referral Hospital, Kampala, Uganda",high
Ojulong2009-Uganda-Mulago-2007-01,burden_incidence,"epidemiology of SSI (incidence, trends)","Staphylococcus aureus is highly prevalent (28.7%) in surgical site infections in Mulago Hospital, Uganda.","Out of the 188 specimen cultured, 54 (28.7%) grew S. aureus.",4,Abstract,"Mulago National Referral Hospital, Kampala, Uganda",high
Ojulong2009-Uganda-Mulago-2007-01,burden_incidence,"epidemiology of SSI (incidence, trends)","Staphylococcus aureus is highly prevalent (28.7%) in surgical site infections in Mulago Hospital, Uganda.","S. aureus is highly (28.7%) prevalent in surgical site infections in Mulago National Referral Hospital, Kampala Uganda.",12,Conclusion,"Mulago National Referral Hospital, Kampala, Uganda",high
Ojulong2009-Uganda-Mulago-2007-01,drivers_amr,"determinants (inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors)",Indiscriminate use of antibiotics may explain the observed MRSA prevalence in SSI at Mulago Hospital.,"Emergence of documented multi-drug resistance bacteria pathogens (Agwu et al., 2004) due to indiscriminate use of antibiotics (Agwu et al., 2005) may explain the observed 31.5% prevalence of MRSA in SSI at the Mulago National Referral Hospital Kampala, Uganda.",10,Discussion,"Mulago National Referral Hospital, Kampala, Uganda",moderate
Scherbaum2014-Gabon-Lambarene-2009-01,burden_incidence,epidemiology of SSI,"The cumulative incidence of nosocomial infections was low overall, but surgical site infections comprised the largest proportion.",The cumulative incidence of nosocomial infections was 1.6 infections per 100 patients in six months (95% CI 1.1 - 2.0) or 3.6 infections per 1000 in-patient days (95% CI 2.6 – 4.6).,3,Results,"Albert Schweitzer Hospital, Lambaréné, Gabon",high
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,High rates of ESBL-producing E. coli and K. pneumoniae were found among nosocomial infection isolates.,Eight (40%) of 20 identified E. coli and Klebsiella spp. strains were ESBL-producing organisms.,1,Abstract,"Albert Schweitzer Hospital, Lambaréné, Gabon",high
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,High rates of ESBL-producing E. coli and K. pneumoniae were found among nosocomial infection isolates.,One of our most striking findings was the fact that five of 14 E. coli strains (36%) and three of six K. pneumoniae strains (50%) were ESBL-producers.,5,Discussion and conclusions,"Albert Schweitzer Hospital, Lambaréné, Gabon",high
Scherbaum2014-Gabon-Lambarene-2009-01,drivers_amr,inappropriate use,"Inappropriate use of antibiotics, including routine prophylaxis of long duration, is a major factor favoring infection with multi-resistant pathogens.",These findings support the view that inappropriate use of anti-infectious medications including routine antibiotic prophylaxis of long duration is a major factor favouring infection with multi-resistant pathogens.,6,Discussion and conclusions,"Albert Schweitzer Hospital, Lambaréné, Gabon",moderate
Scherbaum2014-Gabon-Lambarene-2009-01,outcomes_clinical,"morbidity, mortality, complications",Nosocomial infections led to increased length of stay and in-hospital mortality among affected patients.,"With a mean stay of 27 (range: 4–108) days, patients with nosocomial infections stayed in hospital for 23 days longer than the average patient.",6,Discussion and conclusions,"Albert Schweitzer Hospital, Lambaréné, Gabon",high
Scherbaum2014-Gabon-Lambarene-2009-01,outcomes_clinical,"morbidity, mortality, complications",Nosocomial infections led to increased length of stay and in-hospital mortality among affected patients.,During the study four (11%) of the patients with nosocomial infections died.,3,Results,"Albert Schweitzer Hospital, Lambaréné, Gabon",high
Scherbaum2014-Gabon-Lambarene-2009-01,prevention_control,"IPC programs, bundles, surveillance practices",Detailed surveillance of nosocomial infections is mandatory to reduce hospital-acquired infections and improve patient outcomes.,We also showed that at small rural hospitals detailed surveillance of nosocomial infections is mandatory to be able to reduce hospital-acquired infections and improve patient outcome.,7,Discussion and conclusions,"Albert Schweitzer Hospital, Lambaréné, Gabon",moderate
Scherbaum2014-Gabon-Lambarene-2009-01,interventions_innovations,antibiotic stewardship,"Introducing antibiotic stewardship measures, including appropriate use of antibiotics, is recommended to reduce multiresistant pathogens.","These could, for example, consist of introducing antibiotic stewardship measures which includes appropriate use of antibiotic medications in the hospital setting.",7,Discussion and conclusions,"Albert Schweitzer Hospital, Lambaréné, Gabon",moderate
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,burden_incidence,epidemiology of SSI,"SSI incidence after cesarean section in rural Rwanda was 5.7% at POD 11, with most infections being superficial.","Among the 795 women who completed the POD 11 study visit, 45 (5.7%) were diagnosed with an SSI. Most (n = 40, 88.9%) SSIs were described as superficial, and five (11.1%) were deep.",4,DETAILS OF SURGICAL SITE INFECTIONS,"Kirehe District Hospital, Rwanda",high
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"Gram-negative pathogens predominated in SSI wound cultures and showed high rates of resistance to commonly used antibiotics, including universal resistance to ampicillin and high resistance to ceftriaxone and cefepime.","No gram-negative pathogens isolated were susceptible to ampicillin, and the vast majority demonstrated intermediate susceptibility or resistance to ceftriaxone (92.1%) and cefepime (84.6%).",1,ABSTRACT,"Kirehe District Hospital, Rwanda",high
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,drivers_amr,inappropriate use,"Universal ampicillin resistance may be due to its frequent use pre- and post-operatively, suggesting antibiotic selection pressure.","Universal ampicillin resistance among bacterial SSI isolates in this study may be a result of its long-term and frequent use preoperatively, and could indicate the need to reconsider its use as a post-operative prescription also, as it is likely adding to further resistance–with limited clinical benefit.",7,DISCUSSION,"Kirehe District Hospital, Rwanda",moderate
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,prevention_control,surveillance practices,"SSI diagnosis was performed at POD 11 (+/- 3 days) using CDC guidelines and trained GPs, with wound swabs collected for microbiology.","Before commencing data collection, two study GPs were trained to diagnose SSIs using the Center for Disease Control and Prevention guidelines [25] and to collect swabs.",3,"STUDY POPULATION, DATA AND SAMPLE COLLECTION","Kirehe District Hospital, Rwanda",high
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,microbiology_diagnostics,"lab capacity, methods",Microbiology cultures and AST were performed at the National Reference Laboratory using VITEK2; blood agar was prepared with human blood due to lack of sheep's blood.,"Due to difficulties procuring sheep’s blood in Rwanda, human blood obtained from the National Transfusion Center was used to prepare blood agar plates, following NRL standard practice.",4,TRANSPORT AND PROCESSING OF SAMPLES,"National Reference Laboratory, Kigali, Rwanda",high
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,evidence_gaps,explicit gaps and research priorities,Additional research is needed to determine risk factors contributing to high prevalence of gram-negative and resistant pathogens in rural Rwanda.,Additional research is needed to determine risk factors contributing to the high prevalence of gram-negative and resistant pathogens identified in order to guide context-appropriate care and mitigate infection risks.,8,CONCLUSIONS,"Kirehe District Hospital, Rwanda",high
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"Almost all E. coli and Klebsiella species isolated from post-caesarean SSIs were resistant to ceftriaxone and ceftazidime, with high rates of ESBL and carbapenemase production.",Resistance to ceftriaxone was detected in all 11 (100%) of the E. coli and in 43 (97.7%) of the 44 Klebsiella species and to ceftazidime in all 11 (100%) of the E. coli and 40 (91%) of the 44 Klebsiella species.,1,Abstract,"Mulago National Referral Hospital, Kampala, Uganda",high
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"Almost all E. coli and Klebsiella species isolated from post-caesarean SSIs were resistant to ceftriaxone and ceftazidime, with high rates of ESBL and carbapenemase production.",Extended-spectrum beta-lactamase explained resistance to ceftazidime in 10 (91%) of the 11 E. coli and 19 (48%) of the 40 Klebsiella species. Carbapenemase production explained 15 (38%) of the 40 ceftazidime-resistant Klebsiella species.,1,Abstract,"Mulago National Referral Hospital, Kampala, Uganda",high
Wekesa2020-Uganda-MulagoHospital-201711201804-01,drivers_amr,inappropriate use,Routine use of broad-spectrum antibiotics such as ceftriaxone for prophylaxis and treatment may contribute to high resistance rates among SSI pathogens.,"The use of the hitherto broad-spectrum drugs, such as ceftriaxone, for prophylaxis, and other instances of inappropriate use of such agents, has been suspected as one of the underlying causes of resistance.",9,Discussion,"Mulago National Referral Hospital, Kampala, Uganda",moderate
Wekesa2020-Uganda-MulagoHospital-201711201804-01,prevention_control,surveillance practices,Routine culture and antimicrobial susceptibility testing are recommended to optimize antimicrobial regimens for post-caesarean SSIs.,We strongly recommend routine culture and AST on post-C/S SSIs to optimise antimicrobial regimens for each patient.,10,Conclusion,"Mulago National Referral Hospital, Kampala, Uganda",high
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"High prevalence of ESBL and carbapenemase-producing Acinetobacter baumannii was detected among SSI patients in Ethiopian hospitals, with alarming rates of resistance to ceftriaxone, ceftazidime, and carbapenems.",The frequency of Acinetobacter species that produce metallobetalactamases (MBLs) and ESBLs that were found in this study is extremely scary and calls for strict infection prevention and control procedures in health facilities helps to set effective antibiotics stewardship.,1,Abstract,"Ethiopia, four tertiary hospitals",high
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"High prevalence of ESBL and carbapenemase-producing Acinetobacter baumannii was detected among SSI patients in Ethiopian hospitals, with alarming rates of resistance to ceftriaxone, ceftazidime, and carbapenems.","Of the total 43 Acinetobacter isolates, 95.3% (41/43) were resistant to ceftriaxone, and 93% (40/43), were confirmed for ESBL production by combined disk-diffusion (CDT)",5,Results,"Ethiopia, four tertiary hospitals",high
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"High prevalence of ESBL and carbapenemase-producing Acinetobacter baumannii was detected among SSI patients in Ethiopian hospitals, with alarming rates of resistance to ceftriaxone, ceftazidime, and carbapenems.","In this finding 43 (85.7%) isolates were carbapenem-resistant, which is similar with a study conducted in Pakistan (89.1%) [35].",10,Discussion,"Ethiopia, four tertiary hospitals",high
Worku2024-Ethiopia-Multicenter-2020-2021-1,drivers_amr,"inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors",Extensive antibiotic misuse and poor stewardship have contributed to the rapid spread of resistance to third generation cephalosporins and carbapenems among Acinetobacter species.,"However, due to extensive antibiotic misuse and poor stewardship, resistance to third generation cephalosporins has spread rapidly.",2,Introduction,"Ethiopia, hospital settings",moderate
Worku2024-Ethiopia-Multicenter-2020-2021-1,prevention_control,"IPC programs, bundles, surveillance practices",The high prevalence of ESBL and carbapenemase-producing Acinetobacter species highlights the urgent need for strict infection prevention and control measures in Ethiopian hospitals.,The frequency of Acinetobacter species that produce metallobetalactamases (MBLs) and ESBLs that were found in this study is extremely scary and calls for strict infection prevention and control procedures in health facilities helps to set effective antibiotics stewardship.,1,Abstract,"Ethiopia, hospital settings",high
Worku2024-Ethiopia-Multicenter-2020-2021-1,prevention_control,"IPC programs, bundles, surveillance practices",The high prevalence of ESBL and carbapenemase-producing Acinetobacter species highlights the urgent need for strict infection prevention and control measures in Ethiopian hospitals.,and highlights the need for infection prevention and control measures.,11,Conclusions,"Ethiopia, hospital settings",high
Worku2023-Ethiopia-FourHospitals-2020-2021-1,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"MRSA prevalence among S. aureus isolates was 24.5%, with 27.5% of methicillin-resistant Staphylococci carrying the mecA gene; vancomycin resistance was rare.","S. aureus was identified in 21.6% of participants, with 24.5% of these being methicillin-resistant Staphylococci and 0.6% showing vancomycin resistance.",1,Abstract,"Ethiopia, four tertiary hospitals",high
Worku2023-Ethiopia-FourHospitals-2020-2021-1,amr_prevalence,resistance patterns and rates by pathogen/antibiotic,"MRSA prevalence among S. aureus isolates was 24.5%, with 27.5% of methicillin-resistant Staphylococci carrying the mecA gene; vancomycin resistance was rare.","Of all participants, 5.3% (40/752) carried bacteria characterized as MRSA, while among isolates of S. aureus, the frequency of MRSA was 24.5%.",3,Results,"Ethiopia, four tertiary hospitals",high
Worku2023-Ethiopia-FourHospitals-2020-2021-1,drivers_amr,"determinants (inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors)","Older age, prolonged hospital stay, previous antibiotic use, and intraoperative prophylaxis were associated with increased risk of MRSA SSI.","Methicillin-resistant staphylococcal infections were associated with the following risk factors: age ≥61 years, prolonged duration of hospital stay, and history of previous antibiotic use, p-values < 0.05.",1,Abstract,"Ethiopia, four tertiary hospitals",high
Worku2023-Ethiopia-FourHospitals-2020-2021-1,drivers_amr,"determinants (inappropriate use, IPC gaps, diagnostics delays, policy failures, supply chain, workforce, patient factors)","Older age, prolonged hospital stay, previous antibiotic use, and intraoperative prophylaxis were associated with increased risk of MRSA SSI.",The likelihood of MRSA SSI occurrence was about 3.7 times higher among patients aged ≥61 (AOR = 3.729 (1.179–11.791)) compared to those aged ≤60.,3,Results,"Ethiopia, four tertiary hospitals",high
Worku2023-Ethiopia-FourHospitals-2020-2021-1,prevention_control,"IPC programs, bundles, surveillance practices",Hospitals should strengthen infection prevention and control strategies and start antimicrobial stewardship programs.,Hospitals should strengthen infection prevention and control strategies and start antimicrobial stewardship programs.,1,Abstract,"Ethiopia, four tertiary hospitals",moderate
Varghese2024-Multicountry-FALCON-2018-2020-01,burden_incidence,overall_incidence,"SSI incidence 1163/5284 (22.01%) in Benin, Ghana, India, Mexico, Nigeria, Rwanda, South Africa, general, 2018-2020",,,,,
Varghese2024-Multicountry-FALCON-2018-2020-01,burden_incidence,specialty_specific,"SSI incidence 1163/5284 (22.01%) in Benin, Ghana, India, Mexico, Nigeria, Rwanda, South Africa, general, 2018-2020",,,,,
Varghese2024-Multicountry-FALCON-2018-2020-01,burden_incidence,geographic_variation,"SSI incidence 1163/5284 (22.01%) in Benin, Ghana, India, Mexico, Nigeria, Rwanda, South Africa, general, 2018-2020",,,,,
Varghese2024-Multicountry-FALCON-2018-2020-01,burden_incidence,temporal_trends,"SSI incidence 1163/5284 (22.01%) in Benin, Ghana, India, Mexico, Nigeria, Rwanda, South Africa, general, 2018-2020",,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,burden_incidence,overall_incidence,"SSI incidence 33/262 (12.6%) in Ethiopia, obstetrics/gynecology, 2021-2021",,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,burden_incidence,specialty_specific,"SSI incidence 33/262 (12.6%) in Ethiopia, obstetrics/gynecology, 2021-2021",,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,burden_incidence,geographic_variation,"SSI incidence 33/262 (12.6%) in Ethiopia, obstetrics/gynecology, 2021-2021",,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,burden_incidence,overall_incidence,"SSI incidence 115/165 (69.7%) in Ethiopia, general, 2019-2019",,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,burden_incidence,specialty_specific,"SSI incidence 115/165 (69.7%) in Ethiopia, general, 2019-2019",,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,burden_incidence,geographic_variation,"SSI incidence 115/165 (69.7%) in Ethiopia, general, 2019-2019",,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,burden_incidence,overall_incidence,"SSI incidence 49/338 (14.5%) in Ethiopia, general, 2016-2016",,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,burden_incidence,specialty_specific,"SSI incidence 49/338 (14.5%) in Ethiopia, general, 2016-2016",,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,burden_incidence,geographic_variation,"SSI incidence 49/338 (14.5%) in Ethiopia, general, 2016-2016",,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,burden_incidence,overall_incidence,"SSI incidence 41/338 (12.13%) in Ethiopia, general, 2016-2016",,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,burden_incidence,specialty_specific,"SSI incidence 41/338 (12.13%) in Ethiopia, general, 2016-2016",,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,burden_incidence,geographic_variation,"SSI incidence 41/338 (12.13%) in Ethiopia, general, 2016-2016",,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,burden_incidence,overall_incidence,"SSI incidence 42/255 (16.47%) in Ethiopia, general, 2017-2017",,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,burden_incidence,specialty_specific,"SSI incidence 42/255 (16.47%) in Ethiopia, general, 2017-2017",,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,burden_incidence,geographic_variation,"SSI incidence 42/255 (16.47%) in Ethiopia, general, 2017-2017",,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,burden_incidence,overall_incidence,"SSI incidence 15/144 (10.42%) in Ethiopia, general, 2017-2017",,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,burden_incidence,specialty_specific,"SSI incidence 15/144 (10.42%) in Ethiopia, general, 2017-2017",,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,burden_incidence,geographic_variation,"SSI incidence 15/144 (10.42%) in Ethiopia, general, 2017-2017",,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,burden_incidence,overall_incidence,"SSI incidence 27/111 (24.32%) in Ethiopia, general, 2017-2017",,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,burden_incidence,specialty_specific,"SSI incidence 27/111 (24.32%) in Ethiopia, general, 2017-2017",,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,burden_incidence,geographic_variation,"SSI incidence 27/111 (24.32%) in Ethiopia, general, 2017-2017",,,,,
Boru2025-Ethiopia-BuleHora-2023-01,burden_incidence,overall_incidence,"SSI incidence 29/183 (15.85%) in Ethiopia, general, 2023-2023",,,,,
Boru2025-Ethiopia-BuleHora-2023-01,burden_incidence,specialty_specific,"SSI incidence 29/183 (15.85%) in Ethiopia, general, 2023-2023",,,,,
Boru2025-Ethiopia-BuleHora-2023-01,burden_incidence,geographic_variation,"SSI incidence 29/183 (15.85%) in Ethiopia, general, 2023-2023",,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,burden_incidence,overall_incidence,"SSI incidence 45/62 (72.58%) in Kenya, general",,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,burden_incidence,specialty_specific,"SSI incidence 45/62 (72.58%) in Kenya, general",,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,burden_incidence,geographic_variation,"SSI incidence 45/62 (72.58%) in Kenya, general",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,overall_incidence,"SSI incidence 12/171 (7.02%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,specialty_specific,"SSI incidence 12/171 (7.02%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,geographic_variation,"SSI incidence 12/171 (7.02%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,temporal_trends,"SSI incidence 12/171 (7.02%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,overall_incidence,"SSI incidence 39/268 (14.55%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,specialty_specific,"SSI incidence 39/268 (14.55%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,geographic_variation,"SSI incidence 39/268 (14.55%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,temporal_trends,"SSI incidence 39/268 (14.55%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,overall_incidence,"SSI incidence 5/91 (5.49%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,specialty_specific,"SSI incidence 5/91 (5.49%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,geographic_variation,"SSI incidence 5/91 (5.49%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,temporal_trends,"SSI incidence 5/91 (5.49%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,overall_incidence,"SSI incidence 7/80 (8.75%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,specialty_specific,"SSI incidence 7/80 (8.75%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,geographic_variation,"SSI incidence 7/80 (8.75%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,temporal_trends,"SSI incidence 7/80 (8.75%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,overall_incidence,"SSI incidence 6/30 (20.0%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,specialty_specific,"SSI incidence 6/30 (20.0%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,geographic_variation,"SSI incidence 6/30 (20.0%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,temporal_trends,"SSI incidence 6/30 (20.0%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,overall_incidence,"SSI incidence 20/67 (29.85%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,specialty_specific,"SSI incidence 20/67 (29.85%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,geographic_variation,"SSI incidence 20/67 (29.85%) in Kenya, general, 2008-2009",,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,burden_incidence,temporal_trends,"SSI incidence 20/67 (29.85%) in Kenya, general, 2008-2009",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,overall_incidence,"SSI incidence 225/467 (48.18%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,specialty_specific,"SSI incidence 225/467 (48.18%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,geographic_variation,"SSI incidence 225/467 (48.18%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,overall_incidence,"SSI incidence 95/573 (16.58%) in Tanzania, obstetrics/gynecology, 2015-2015",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,specialty_specific,"SSI incidence 95/573 (16.58%) in Tanzania, obstetrics/gynecology, 2015-2015",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,geographic_variation,"SSI incidence 95/573 (16.58%) in Tanzania, obstetrics/gynecology, 2015-2015",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,overall_incidence,"SSI incidence 138/225 (61.33%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,specialty_specific,"SSI incidence 138/225 (61.33%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,geographic_variation,"SSI incidence 138/225 (61.33%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,overall_incidence,"SSI incidence 74/225 (32.89%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,specialty_specific,"SSI incidence 74/225 (32.89%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,geographic_variation,"SSI incidence 74/225 (32.89%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,overall_incidence,"SSI incidence 80/95 (84.21%) in Tanzania, obstetrics/gynecology, 2015-2015",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,specialty_specific,"SSI incidence 80/95 (84.21%) in Tanzania, obstetrics/gynecology, 2015-2015",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,geographic_variation,"SSI incidence 80/95 (84.21%) in Tanzania, obstetrics/gynecology, 2015-2015",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,overall_incidence,"SSI incidence 11/95 (11.58%) in Tanzania, obstetrics/gynecology, 2015-2015",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,specialty_specific,"SSI incidence 11/95 (11.58%) in Tanzania, obstetrics/gynecology, 2015-2015",,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,burden_incidence,geographic_variation,"SSI incidence 11/95 (11.58%) in Tanzania, obstetrics/gynecology, 2015-2015",,,,,
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,burden_incidence,overall_incidence,"SSI incidence 126/204 (61.76%) in Ethiopia, general, 2022-2023",,,,,
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,burden_incidence,specialty_specific,"SSI incidence 126/204 (61.76%) in Ethiopia, general, 2022-2023",,,,,
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,burden_incidence,geographic_variation,"SSI incidence 126/204 (61.76%) in Ethiopia, general, 2022-2023",,,,,
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,burden_incidence,temporal_trends,"SSI incidence 126/204 (61.76%) in Ethiopia, general, 2022-2023",,,,,
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,burden_incidence,overall_incidence,"SSI incidence 73/126 (57.94%) in Ethiopia, general, 2022-2023",,,,,
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,burden_incidence,specialty_specific,"SSI incidence 73/126 (57.94%) in Ethiopia, general, 2022-2023",,,,,
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,burden_incidence,geographic_variation,"SSI incidence 73/126 (57.94%) in Ethiopia, general, 2022-2023",,,,,
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,burden_incidence,temporal_trends,"SSI incidence 73/126 (57.94%) in Ethiopia, general, 2022-2023",,,,,
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,burden_incidence,overall_incidence,"SSI incidence 53/126 (42.06%) in Ethiopia, general, 2022-2023",,,,,
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,burden_incidence,specialty_specific,"SSI incidence 53/126 (42.06%) in Ethiopia, general, 2022-2023",,,,,
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,burden_incidence,geographic_variation,"SSI incidence 53/126 (42.06%) in Ethiopia, general, 2022-2023",,,,,
Habteweld2023-Ethiopia-DebreBerhan-202210202301-01,burden_incidence,temporal_trends,"SSI incidence 53/126 (42.06%) in Ethiopia, general, 2022-2023",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,overall_incidence,"SSI incidence 36/120 (30.0%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,specialty_specific,"SSI incidence 36/120 (30.0%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,geographic_variation,"SSI incidence 36/120 (30.0%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,overall_incidence,"SSI incidence 23/90 (25.56%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,specialty_specific,"SSI incidence 23/90 (25.56%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,geographic_variation,"SSI incidence 23/90 (25.56%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,overall_incidence,"SSI incidence 13/30 (43.33%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,specialty_specific,"SSI incidence 13/30 (43.33%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,geographic_variation,"SSI incidence 13/30 (43.33%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,overall_incidence,"SSI incidence 28/36 (77.78%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,specialty_specific,"SSI incidence 28/36 (77.78%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,geographic_variation,"SSI incidence 28/36 (77.78%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,overall_incidence,"SSI incidence 8/36 (22.22%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,specialty_specific,"SSI incidence 8/36 (22.22%) in Tanzania, orthopedics, 2024-2024",,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,burden_incidence,geographic_variation,"SSI incidence 8/36 (22.22%) in Tanzania, orthopedics, 2024-2024",,,,,
Kachipedzu2024-Malawi-QECH-2023-1,burden_incidence,overall_incidence,"SSI incidence 20/208 (9.62%) in Malawi, obstetrics/gynecology, 2023-2023",,,,,
Kachipedzu2024-Malawi-QECH-2023-1,burden_incidence,specialty_specific,"SSI incidence 20/208 (9.62%) in Malawi, obstetrics/gynecology, 2023-2023",,,,,
Kachipedzu2024-Malawi-QECH-2023-1,burden_incidence,geographic_variation,"SSI incidence 20/208 (9.62%) in Malawi, obstetrics/gynecology, 2023-2023",,,,,
Kachipedzu2024-Malawi-QECH-2023-1,burden_incidence,overall_incidence,"SSI incidence 19/208 (9.13%) in Malawi, obstetrics/gynecology, 2023-2023",,,,,
Kachipedzu2024-Malawi-QECH-2023-1,burden_incidence,specialty_specific,"SSI incidence 19/208 (9.13%) in Malawi, obstetrics/gynecology, 2023-2023",,,,,
Kachipedzu2024-Malawi-QECH-2023-1,burden_incidence,geographic_variation,"SSI incidence 19/208 (9.13%) in Malawi, obstetrics/gynecology, 2023-2023",,,,,
Kachipedzu2024-Malawi-QECH-2023-1,burden_incidence,overall_incidence,"SSI incidence 1/208 (0.48%) in Malawi, obstetrics/gynecology, 2023-2023",,,,,
Kachipedzu2024-Malawi-QECH-2023-1,burden_incidence,specialty_specific,"SSI incidence 1/208 (0.48%) in Malawi, obstetrics/gynecology, 2023-2023",,,,,
Kachipedzu2024-Malawi-QECH-2023-1,burden_incidence,geographic_variation,"SSI incidence 1/208 (0.48%) in Malawi, obstetrics/gynecology, 2023-2023",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,overall_incidence,"SSI incidence 55/281 (19.57%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,specialty_specific,"SSI incidence 55/281 (19.57%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,geographic_variation,"SSI incidence 55/281 (19.57%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,temporal_trends,"SSI incidence 55/281 (19.57%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,overall_incidence,"SSI incidence 41/281 (14.59%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,specialty_specific,"SSI incidence 41/281 (14.59%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,geographic_variation,"SSI incidence 41/281 (14.59%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,temporal_trends,"SSI incidence 41/281 (14.59%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,overall_incidence,"SSI incidence 8/281 (2.85%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,specialty_specific,"SSI incidence 8/281 (2.85%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,geographic_variation,"SSI incidence 8/281 (2.85%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,temporal_trends,"SSI incidence 8/281 (2.85%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,overall_incidence,"SSI incidence 8/281 (2.85%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,specialty_specific,"SSI incidence 8/281 (2.85%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,geographic_variation,"SSI incidence 8/281 (2.85%) in Ethiopia, general, 2019-2020",,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,burden_incidence,temporal_trends,"SSI incidence 8/281 (2.85%) in Ethiopia, general, 2019-2020",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,overall_incidence,"SSI incidence 169/212 (79.72%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,specialty_specific,"SSI incidence 169/212 (79.72%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,geographic_variation,"SSI incidence 169/212 (79.72%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,temporal_trends,"SSI incidence 169/212 (79.72%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,overall_incidence,"SSI incidence 3/3 (100.0%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,specialty_specific,"SSI incidence 3/3 (100.0%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,geographic_variation,"SSI incidence 3/3 (100.0%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,temporal_trends,"SSI incidence 3/3 (100.0%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,overall_incidence,"SSI incidence 13/15 (86.67%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,specialty_specific,"SSI incidence 13/15 (86.67%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,geographic_variation,"SSI incidence 13/15 (86.67%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,temporal_trends,"SSI incidence 13/15 (86.67%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,overall_incidence,"SSI incidence 23/29 (79.31%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,specialty_specific,"SSI incidence 23/29 (79.31%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,geographic_variation,"SSI incidence 23/29 (79.31%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,temporal_trends,"SSI incidence 23/29 (79.31%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,overall_incidence,"SSI incidence 130/165 (78.79%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,specialty_specific,"SSI incidence 130/165 (78.79%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,geographic_variation,"SSI incidence 130/165 (78.79%) in Cameroon, general, 2010-2011",,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,burden_incidence,temporal_trends,"SSI incidence 130/165 (78.79%) in Cameroon, general, 2010-2011",,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,burden_incidence,overall_incidence,"SSI incidence 96/128 (75.0%) in Ethiopia, general, 2012-2012",,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,burden_incidence,specialty_specific,"SSI incidence 96/128 (75.0%) in Ethiopia, general, 2012-2012",,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,burden_incidence,geographic_variation,"SSI incidence 96/128 (75.0%) in Ethiopia, general, 2012-2012",,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,burden_incidence,overall_incidence,"SSI incidence 53/251 (21.12%) in Ethiopia, general, 2019-2019",,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,burden_incidence,specialty_specific,"SSI incidence 53/251 (21.12%) in Ethiopia, general, 2019-2019",,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,burden_incidence,geographic_variation,"SSI incidence 53/251 (21.12%) in Ethiopia, general, 2019-2019",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,overall_incidence,"SSI incidence 34/294 (11.56%) in Rwanda, general, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,specialty_specific,"SSI incidence 34/294 (11.56%) in Rwanda, general, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,geographic_variation,"SSI incidence 34/294 (11.56%) in Rwanda, general, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,temporal_trends,"SSI incidence 34/294 (11.56%) in Rwanda, general, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,overall_incidence,"SSI incidence 26/217 (11.98%) in Rwanda, orthopedics, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,specialty_specific,"SSI incidence 26/217 (11.98%) in Rwanda, orthopedics, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,geographic_variation,"SSI incidence 26/217 (11.98%) in Rwanda, orthopedics, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,temporal_trends,"SSI incidence 26/217 (11.98%) in Rwanda, orthopedics, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,overall_incidence,"SSI incidence 8/66 (12.12%) in Rwanda, general, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,specialty_specific,"SSI incidence 8/66 (12.12%) in Rwanda, general, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,geographic_variation,"SSI incidence 8/66 (12.12%) in Rwanda, general, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,temporal_trends,"SSI incidence 8/66 (12.12%) in Rwanda, general, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,overall_incidence,"SSI incidence 0/11 (0.0%) in Rwanda, urology, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,specialty_specific,"SSI incidence 0/11 (0.0%) in Rwanda, urology, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,geographic_variation,"SSI incidence 0/11 (0.0%) in Rwanda, urology, 2017-2018",,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,burden_incidence,temporal_trends,"SSI incidence 0/11 (0.0%) in Rwanda, urology, 2017-2018",,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,burden_incidence,overall_incidence,"SSI incidence 225/467 (48.18%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,burden_incidence,specialty_specific,"SSI incidence 225/467 (48.18%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,burden_incidence,geographic_variation,"SSI incidence 225/467 (48.18%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,burden_incidence,overall_incidence,"SSI incidence 138/467 (29.55%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,burden_incidence,specialty_specific,"SSI incidence 138/467 (29.55%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,burden_incidence,geographic_variation,"SSI incidence 138/467 (29.55%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,burden_incidence,overall_incidence,"SSI incidence 69/467 (14.78%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,burden_incidence,specialty_specific,"SSI incidence 69/467 (14.78%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,burden_incidence,geographic_variation,"SSI incidence 69/467 (14.78%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,burden_incidence,overall_incidence,"SSI incidence 5/467 (1.07%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,burden_incidence,specialty_specific,"SSI incidence 5/467 (1.07%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,burden_incidence,geographic_variation,"SSI incidence 5/467 (1.07%) in Tanzania, obstetrics/gynecology, 2013-2013",,,,,
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,burden_incidence,overall_incidence,"SSI incidence 8/147 (5.44%) in Rwanda, obstetrics/gynecology, 2015-2016",,,,,
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,burden_incidence,specialty_specific,"SSI incidence 8/147 (5.44%) in Rwanda, obstetrics/gynecology, 2015-2016",,,,,
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,burden_incidence,geographic_variation,"SSI incidence 8/147 (5.44%) in Rwanda, obstetrics/gynecology, 2015-2016",,,,,
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,burden_incidence,temporal_trends,"SSI incidence 8/147 (5.44%) in Rwanda, obstetrics/gynecology, 2015-2016",,,,,
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,burden_incidence,overall_incidence,"SSI incidence 4/154 (2.6%) in Rwanda, obstetrics/gynecology, 2015-2016",,,,,
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,burden_incidence,specialty_specific,"SSI incidence 4/154 (2.6%) in Rwanda, obstetrics/gynecology, 2015-2016",,,,,
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,burden_incidence,geographic_variation,"SSI incidence 4/154 (2.6%) in Rwanda, obstetrics/gynecology, 2015-2016",,,,,
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,burden_incidence,temporal_trends,"SSI incidence 4/154 (2.6%) in Rwanda, obstetrics/gynecology, 2015-2016",,,,,
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,burden_incidence,overall_incidence,"SSI incidence 12/301 (3.99%) in Rwanda, obstetrics/gynecology, 2015-2016",,,,,
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,burden_incidence,specialty_specific,"SSI incidence 12/301 (3.99%) in Rwanda, obstetrics/gynecology, 2015-2016",,,,,
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,burden_incidence,geographic_variation,"SSI incidence 12/301 (3.99%) in Rwanda, obstetrics/gynecology, 2015-2016",,,,,
Ntirushwa2021-Rwanda-RuhengeriHospital-2015-2016-01,burden_incidence,temporal_trends,"SSI incidence 12/301 (3.99%) in Rwanda, obstetrics/gynecology, 2015-2016",,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,burden_incidence,overall_incidence,"SSI incidence 20/2925 (0.68%) in Gabon, general, 2009-2009",,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,burden_incidence,specialty_specific,"SSI incidence 20/2925 (0.68%) in Gabon, general, 2009-2009",,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,burden_incidence,geographic_variation,"SSI incidence 20/2925 (0.68%) in Gabon, general, 2009-2009",,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,burden_incidence,overall_incidence,"SSI incidence 20/1059 (1.89%) in Gabon, general, 2009-2009",,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,burden_incidence,specialty_specific,"SSI incidence 20/1059 (1.89%) in Gabon, general, 2009-2009",,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,burden_incidence,geographic_variation,"SSI incidence 20/1059 (1.89%) in Gabon, general, 2009-2009",,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,burden_incidence,overall_incidence,"SSI incidence 3/26 (11.54%) in Gabon, obstetrics/gynecology, 2009-2009",,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,burden_incidence,specialty_specific,"SSI incidence 3/26 (11.54%) in Gabon, obstetrics/gynecology, 2009-2009",,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,burden_incidence,geographic_variation,"SSI incidence 3/26 (11.54%) in Gabon, obstetrics/gynecology, 2009-2009",,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,burden_incidence,overall_incidence,"SSI incidence 5/80 (6.25%) in Gabon, obstetrics/gynecology, 2009-2009",,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,burden_incidence,specialty_specific,"SSI incidence 5/80 (6.25%) in Gabon, obstetrics/gynecology, 2009-2009",,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,burden_incidence,geographic_variation,"SSI incidence 5/80 (6.25%) in Gabon, obstetrics/gynecology, 2009-2009",,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,burden_incidence,overall_incidence,"SSI incidence 45/795 (5.66%) in Rwanda, obstetrics/gynecology, 2019-2020",,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,burden_incidence,specialty_specific,"SSI incidence 45/795 (5.66%) in Rwanda, obstetrics/gynecology, 2019-2020",,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,burden_incidence,geographic_variation,"SSI incidence 45/795 (5.66%) in Rwanda, obstetrics/gynecology, 2019-2020",,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,burden_incidence,temporal_trends,"SSI incidence 45/795 (5.66%) in Rwanda, obstetrics/gynecology, 2019-2020",,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,burden_incidence,overall_incidence,"SSI incidence 109/109 (100.0%) in Uganda, obstetrics/gynecology, 2017-2018",,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,burden_incidence,specialty_specific,"SSI incidence 109/109 (100.0%) in Uganda, obstetrics/gynecology, 2017-2018",,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,burden_incidence,geographic_variation,"SSI incidence 109/109 (100.0%) in Uganda, obstetrics/gynecology, 2017-2018",,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,burden_incidence,temporal_trends,"SSI incidence 109/109 (100.0%) in Uganda, obstetrics/gynecology, 2017-2018",,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,burden_incidence,overall_incidence,"SSI incidence 752/752 (100.0%) in Ethiopia, general, 2020-2021",,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,burden_incidence,specialty_specific,"SSI incidence 752/752 (100.0%) in Ethiopia, general, 2020-2021",,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,burden_incidence,geographic_variation,"SSI incidence 752/752 (100.0%) in Ethiopia, general, 2020-2021",,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,burden_incidence,temporal_trends,"SSI incidence 752/752 (100.0%) in Ethiopia, general, 2020-2021",,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,burden_incidence,overall_incidence,"SSI incidence 493/752 (65.56%) in Ethiopia, general, 2020-2021",,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,burden_incidence,specialty_specific,"SSI incidence 493/752 (65.56%) in Ethiopia, general, 2020-2021",,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,burden_incidence,geographic_variation,"SSI incidence 493/752 (65.56%) in Ethiopia, general, 2020-2021",,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,burden_incidence,temporal_trends,"SSI incidence 493/752 (65.56%) in Ethiopia, general, 2020-2021",,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ampicillin: 12/12 (100.0%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ampicillin: 12/12 (100.0%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ampicillin: 12/12 (100.0%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ampicillin: 12/12 (100.0%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ampicillin: 7/8 (87.5%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ampicillin: 7/8 (87.5%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / ampicillin: 7/8 (87.5%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ampicillin: 7/8 (87.5%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / amoxicillin-clavulanate: 11/12 (91.67%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / amoxicillin-clavulanate: 11/12 (91.67%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / amoxicillin-clavulanate: 11/12 (91.67%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / amoxicillin-clavulanate: 11/12 (91.67%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / cefoxitin: 3/8 (37.5%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / cefoxitin: 3/8 (37.5%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / cefoxitin: 3/8 (37.5%),,,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / cefoxitin: 3/8 (37.5%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / amoxicillin: 27/31 (87.1%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / amoxicillin: 27/31 (87.1%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / amoxicillin: 27/31 (87.1%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ampicillin: 22/31 (70.97%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ampicillin: 22/31 (70.97%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ampicillin: 22/31 (70.97%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / vancomycin: 3/31 (9.68%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / vancomycin: 3/31 (9.68%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / vancomycin: 3/31 (9.68%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 5/31 (16.13%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 5/31 (16.13%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 5/31 (16.13%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / ampicillin: 22/26 (84.62%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / ampicillin: 22/26 (84.62%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,specimen_site,AMR prevalence for Pseudomonas aeruginosa / ampicillin: 22/26 (84.62%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / ciprofloxacin: 5/26 (19.23%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / ciprofloxacin: 5/26 (19.23%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,specimen_site,AMR prevalence for Pseudomonas aeruginosa / ciprofloxacin: 5/26 (19.23%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / meropenem: 6/26 (23.08%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / meropenem: 6/26 (23.08%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,specimen_site,AMR prevalence for Pseudomonas aeruginosa / meropenem: 6/26 (23.08%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / ampicillin: 14/17 (82.35%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / ampicillin: 14/17 (82.35%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella spp. / ampicillin: 14/17 (82.35%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / meropenem: 2/17 (11.76%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / meropenem: 2/17 (11.76%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella spp. / meropenem: 2/17 (11.76%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / gentamicin: 2/17 (11.76%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / gentamicin: 2/17 (11.76%),,,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella spp. / gentamicin: 2/17 (11.76%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / penicillin: 14/14 (100.0%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / penicillin: 14/14 (100.0%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / penicillin: 14/14 (100.0%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / penicillin: 14/14 (100.0%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / cefoxitin: 6/14 (42.86%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / cefoxitin: 6/14 (42.86%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / cefoxitin: 6/14 (42.86%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / cefoxitin: 6/14 (42.86%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ampicillin: 8/9 (88.89%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ampicillin: 8/9 (88.89%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ampicillin: 8/9 (88.89%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ampicillin: 8/9 (88.89%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella pneumoniae / ampicillin: 7/7 (100.0%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella pneumoniae / ampicillin: 7/7 (100.0%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Klebsiella pneumoniae / ampicillin: 7/7 (100.0%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella pneumoniae / ampicillin: 7/7 (100.0%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,pathogen_specific,AMR prevalence for Enterobacteriaceae / ampicillin: 21/23 (91.3%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Enterobacteriaceae / ampicillin: 21/23 (91.3%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,specimen_site,AMR prevalence for Enterobacteriaceae / ampicillin: 21/23 (91.3%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / vancomycin: 2/22 (9.09%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / vancomycin: 2/22 (9.09%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / vancomycin: 2/22 (9.09%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 3/22 (13.64%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 3/22 (13.64%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 3/22 (13.64%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / chloramphenicol: 1/22 (4.55%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / chloramphenicol: 1/22 (4.55%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / chloramphenicol: 1/22 (4.55%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ampicillin: 21/22 (95.45%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ampicillin: 21/22 (95.45%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ampicillin: 21/22 (95.45%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / oxacillin: 13/22 (59.09%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / oxacillin: 13/22 (59.09%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / oxacillin: 13/22 (59.09%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / chloramphenicol: 7/12 (58.33%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / chloramphenicol: 7/12 (58.33%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / chloramphenicol: 7/12 (58.33%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ampicillin: 11/12 (91.67%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ampicillin: 11/12 (91.67%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ampicillin: 11/12 (91.67%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,pathogen_specific,AMR prevalence for Acinetobacter baumannii / amikacin: 6/11 (54.55%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Acinetobacter baumannii / amikacin: 6/11 (54.55%),,,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,specimen_site,AMR prevalence for Acinetobacter baumannii / amikacin: 6/11 (54.55%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella pneumoniae / ceftriaxone: 1/9 (11.11%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella pneumoniae / ceftriaxone: 1/9 (11.11%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella pneumoniae / ceftriaxone: 1/9 (11.11%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella pneumoniae / ciprofloxacin: 1/9 (11.11%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella pneumoniae / ciprofloxacin: 1/9 (11.11%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella pneumoniae / ciprofloxacin: 1/9 (11.11%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella pneumoniae / gentamicin: 3/9 (33.33%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella pneumoniae / gentamicin: 3/9 (33.33%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella pneumoniae / gentamicin: 3/9 (33.33%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella pneumoniae / chloramphenicol: 2/6 (33.33%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella pneumoniae / chloramphenicol: 2/6 (33.33%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella pneumoniae / chloramphenicol: 2/6 (33.33%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ceftriaxone: 0/3 (0.0%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ceftriaxone: 0/3 (0.0%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ceftriaxone: 0/3 (0.0%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 1/4 (25.0%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 1/4 (25.0%),,,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 1/4 (25.0%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / chloramphenicol: 1/14 (7.14%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / chloramphenicol: 1/14 (7.14%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / chloramphenicol: 1/14 (7.14%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / chloramphenicol: 1/14 (7.14%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / cefoxitin: 8/14 (57.14%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / cefoxitin: 8/14 (57.14%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / cefoxitin: 8/14 (57.14%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / cefoxitin: 8/14 (57.14%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / penicillin: 8/14 (57.14%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / penicillin: 8/14 (57.14%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / penicillin: 8/14 (57.14%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / penicillin: 8/14 (57.14%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ampicillin: 5/6 (83.33%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ampicillin: 5/6 (83.33%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ampicillin: 5/6 (83.33%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ampicillin: 5/6 (83.33%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ceftazidime: 5/6 (83.33%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ceftazidime: 5/6 (83.33%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ceftazidime: 5/6 (83.33%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ceftazidime: 5/6 (83.33%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / ciprofloxacin: 0/6 (0.0%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / ciprofloxacin: 0/6 (0.0%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Pseudomonas aeruginosa / ciprofloxacin: 0/6 (0.0%),,,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,specimen_site,AMR prevalence for Pseudomonas aeruginosa / ciprofloxacin: 0/6 (0.0%),,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ceftriaxone: 11/12 (91.67%),,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ceftriaxone: 11/12 (91.67%),,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ceftriaxone: 11/12 (91.67%),,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,pathogen_specific,AMR prevalence for Proteus spp. / ceftriaxone: 3/4 (75.0%),,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Proteus spp. / ceftriaxone: 3/4 (75.0%),,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,specimen_site,AMR prevalence for Proteus spp. / ceftriaxone: 3/4 (75.0%),,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / oxacillin: 9/16 (56.25%),,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / oxacillin: 9/16 (56.25%),,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / oxacillin: 9/16 (56.25%),,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,pathogen_specific,AMR prevalence for Enterococcus faecalis / vancomycin: 3/4 (75.0%),,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Enterococcus faecalis / vancomycin: 3/4 (75.0%),,,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,specimen_site,AMR prevalence for Enterococcus faecalis / vancomycin: 3/4 (75.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ampicillin: 6/10 (60.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ampicillin: 6/10 (60.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ampicillin: 6/10 (60.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / doxycycline: 4/10 (40.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / doxycycline: 4/10 (40.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / azithromycin: 3/10 (30.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / azithromycin: 3/10 (30.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / amoxicillin-clavulanate: 1/10 (10.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / amoxicillin-clavulanate: 1/10 (10.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / cefuroxime: 1/10 (10.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / cefuroxime: 1/10 (10.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 5/10 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 5/10 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / chloramphenicol: 2/10 (20.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / chloramphenicol: 2/10 (20.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / oxacillin: 1/10 (10.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / oxacillin: 1/10 (10.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / netilmicin: 0/10 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / netilmicin: 0/10 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / vancomycin: 0/10 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / vancomycin: 0/10 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Coagulase-negative staphylococci / ampicillin: 4/5 (80.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Coagulase-negative staphylococci / ampicillin: 4/5 (80.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Coagulase-negative staphylococci / doxycycline: 3/5 (60.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Coagulase-negative staphylococci / doxycycline: 3/5 (60.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Coagulase-negative staphylococci / azithromycin: 3/5 (60.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Coagulase-negative staphylococci / azithromycin: 3/5 (60.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Coagulase-negative staphylococci / amoxicillin-clavulanate: 2/5 (40.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Coagulase-negative staphylococci / amoxicillin-clavulanate: 2/5 (40.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Coagulase-negative staphylococci / cefuroxime: 3/5 (60.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Coagulase-negative staphylococci / cefuroxime: 3/5 (60.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Coagulase-negative staphylococci / ciprofloxacin: 1/5 (20.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Coagulase-negative staphylococci / ciprofloxacin: 1/5 (20.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Coagulase-negative staphylococci / chloramphenicol: 2/5 (40.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Coagulase-negative staphylococci / chloramphenicol: 2/5 (40.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Coagulase-negative staphylococci / oxacillin: 0/5 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Coagulase-negative staphylococci / oxacillin: 0/5 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Coagulase-negative staphylococci / netilmicin: 0/5 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Coagulase-negative staphylococci / netilmicin: 0/5 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Coagulase-negative staphylococci / vancomycin: 0/5 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Coagulase-negative staphylococci / vancomycin: 0/5 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Kluyvera spp. / co-trimoxazole: 0/4 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Kluyvera spp. / co-trimoxazole: 0/4 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Kluyvera spp. / doxycycline: 3/4 (75.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Kluyvera spp. / doxycycline: 3/4 (75.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Kluyvera spp. / amoxicillin-clavulanate: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Kluyvera spp. / amoxicillin-clavulanate: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Kluyvera spp. / cefotaxime: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Kluyvera spp. / cefotaxime: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Kluyvera spp. / chloramphenicol: 1/4 (25.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Kluyvera spp. / chloramphenicol: 1/4 (25.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Kluyvera spp. / cefuroxime: 1/4 (25.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Kluyvera spp. / cefuroxime: 1/4 (25.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Kluyvera spp. / ciprofloxacin: 1/4 (25.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Kluyvera spp. / ciprofloxacin: 1/4 (25.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Kluyvera spp. / gentamicin: 1/4 (25.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Kluyvera spp. / gentamicin: 1/4 (25.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / co-trimoxazole: 3/4 (75.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / co-trimoxazole: 3/4 (75.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / doxycycline: 3/4 (75.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / doxycycline: 3/4 (75.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / amoxicillin-clavulanate: 3/4 (75.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / amoxicillin-clavulanate: 3/4 (75.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / cefotaxime: 1/4 (25.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / cefotaxime: 1/4 (25.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / chloramphenicol: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / chloramphenicol: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / cefuroxime: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / cefuroxime: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ciprofloxacin: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ciprofloxacin: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / gentamicin: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / gentamicin: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / co-trimoxazole: 2/3 (66.67%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / co-trimoxazole: 2/3 (66.67%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / doxycycline: 1/3 (33.33%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / doxycycline: 1/3 (33.33%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / amoxicillin-clavulanate: 2/3 (66.67%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / amoxicillin-clavulanate: 2/3 (66.67%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / cefotaxime: 2/3 (66.67%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / cefotaxime: 2/3 (66.67%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / chloramphenicol: 1/3 (33.33%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / chloramphenicol: 1/3 (33.33%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / cefuroxime: 0/3 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / cefuroxime: 0/3 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / ciprofloxacin: 0/3 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / ciprofloxacin: 0/3 (0.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / gentamicin: 2/3 (66.67%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / gentamicin: 2/3 (66.67%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / ciprofloxacin: 3/4 (75.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / ciprofloxacin: 3/4 (75.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / gentamicin: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / gentamicin: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / piperacillin-tazobactam: 3/4 (75.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / piperacillin-tazobactam: 3/4 (75.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / cefepime: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / cefepime: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / ceftazidime: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / ceftazidime: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / imipenem: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / imipenem: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / piperacillin: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / piperacillin: 2/4 (50.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / ceftriaxone: 1/4 (25.0%),,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / ceftriaxone: 1/4 (25.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / penicillin: 20/20 (100.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / penicillin: 20/20 (100.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / penicillin: 20/20 (100.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / penicillin: 20/20 (100.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / oxacillin: 14/20 (70.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / oxacillin: 14/20 (70.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / oxacillin: 14/20 (70.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / oxacillin: 14/20 (70.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / vancomycin: 12/20 (60.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / vancomycin: 12/20 (60.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / vancomycin: 12/20 (60.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / vancomycin: 12/20 (60.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / clindamycin: 5/20 (25.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / clindamycin: 5/20 (25.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / clindamycin: 5/20 (25.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / clindamycin: 5/20 (25.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / erythromycin: 5/20 (25.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / erythromycin: 5/20 (25.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / erythromycin: 5/20 (25.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / erythromycin: 5/20 (25.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ampicillin: 10/10 (100.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ampicillin: 10/10 (100.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ampicillin: 10/10 (100.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ampicillin: 10/10 (100.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / trimethoprim-sulfamethoxazole: 9/10 (90.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / trimethoprim-sulfamethoxazole: 9/10 (90.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / trimethoprim-sulfamethoxazole: 9/10 (90.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / trimethoprim-sulfamethoxazole: 9/10 (90.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / gentamicin: 7/10 (70.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / gentamicin: 7/10 (70.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / gentamicin: 7/10 (70.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / gentamicin: 7/10 (70.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ceftazidime: 9/10 (90.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ceftazidime: 9/10 (90.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ceftazidime: 9/10 (90.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ceftazidime: 9/10 (90.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ceftriaxone: 8/10 (80.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ceftriaxone: 8/10 (80.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ceftriaxone: 8/10 (80.0%),,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ceftriaxone: 8/10 (80.0%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / oxacillin: 34/43 (79.07%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / oxacillin: 34/43 (79.07%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / oxacillin: 34/43 (79.07%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / oxacillin: 3/14 (21.43%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / oxacillin: 3/14 (21.43%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / oxacillin: 3/14 (21.43%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / multiple_classes: 4/4 (100.0%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / multiple_classes: 4/4 (100.0%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Klebsiella spp. / multiple_classes: 4/4 (100.0%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,specimen_site,AMR prevalence for Klebsiella spp. / multiple_classes: 4/4 (100.0%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / multiple_classes: 3/7 (42.86%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / multiple_classes: 3/7 (42.86%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Klebsiella spp. / multiple_classes: 3/7 (42.86%),,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,specimen_site,AMR prevalence for Klebsiella spp. / multiple_classes: 3/7 (42.86%),,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ampicillin: 10/11 (90.91%),,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ampicillin: 10/11 (90.91%),,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ampicillin: 10/11 (90.91%),,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ceftriaxone: 4/7 (57.14%),,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ceftriaxone: 4/7 (57.14%),,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ceftriaxone: 4/7 (57.14%),,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / ceftazidime: 1/4 (25.0%),,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / ceftazidime: 1/4 (25.0%),,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,specimen_site,AMR prevalence for Pseudomonas aeruginosa / ceftazidime: 1/4 (25.0%),,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,pathogen_specific,AMR prevalence for Enterococcus faecalis / ampicillin: 1/3 (33.33%),,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Enterococcus faecalis / ampicillin: 1/3 (33.33%),,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,specimen_site,AMR prevalence for Enterococcus faecalis / ampicillin: 1/3 (33.33%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ampicillin: 20/20 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ampicillin: 20/20 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / ampicillin: 20/20 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ampicillin: 20/20 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / oxacillin: 20/20 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / oxacillin: 20/20 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / oxacillin: 20/20 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / oxacillin: 20/20 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / ampicillin: 27/27 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / ampicillin: 27/27 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Klebsiella spp. / ampicillin: 27/27 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella spp. / ampicillin: 27/27 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / ceftriaxone: 23/27 (85.19%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / ceftriaxone: 23/27 (85.19%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Klebsiella spp. / ceftriaxone: 23/27 (85.19%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella spp. / ceftriaxone: 23/27 (85.19%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ampicillin: 9/9 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ampicillin: 9/9 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ampicillin: 9/9 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ampicillin: 9/9 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ceftriaxone: 9/9 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ceftriaxone: 9/9 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ceftriaxone: 9/9 (100.0%),,,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ceftriaxone: 9/9 (100.0%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ampicillin: 58/74 (78.38%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ampicillin: 58/74 (78.38%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ampicillin: 58/74 (78.38%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / amoxicillin-clavulanate: 9/74 (12.16%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / amoxicillin-clavulanate: 9/74 (12.16%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / amoxicillin-clavulanate: 9/74 (12.16%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ceftazidime: 37/74 (50.0%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ceftazidime: 37/74 (50.0%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ceftazidime: 37/74 (50.0%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / cefotaxime: 30/74 (40.54%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / cefotaxime: 30/74 (40.54%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / cefotaxime: 30/74 (40.54%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 50/74 (67.57%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 50/74 (67.57%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 50/74 (67.57%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / clindamycin: 52/74 (70.27%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / clindamycin: 52/74 (70.27%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / clindamycin: 52/74 (70.27%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / cotrimoxazole: 54/74 (72.97%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / cotrimoxazole: 54/74 (72.97%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / cotrimoxazole: 54/74 (72.97%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / erythromycin: 51/74 (68.92%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / erythromycin: 51/74 (68.92%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / erythromycin: 51/74 (68.92%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / imipenem: 0/74 (0.0%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / imipenem: 0/74 (0.0%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / imipenem: 0/74 (0.0%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / vancomycin: 11/74 (14.86%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / vancomycin: 11/74 (14.86%),,,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / vancomycin: 11/74 (14.86%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Acinetobacter baumannii / ceftriaxone: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Acinetobacter baumannii / ceftriaxone: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Acinetobacter baumannii / ceftriaxone: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Acinetobacter baumannii / ciprofloxacin: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Acinetobacter baumannii / ciprofloxacin: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Acinetobacter baumannii / ciprofloxacin: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Acinetobacter baumannii / gentamicin: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Acinetobacter baumannii / gentamicin: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Acinetobacter baumannii / gentamicin: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Acinetobacter baumannii / cefotaxime: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Acinetobacter baumannii / cefotaxime: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Acinetobacter baumannii / cefotaxime: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Acinetobacter baumannii / tigecycline: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Acinetobacter baumannii / tigecycline: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Acinetobacter baumannii / tigecycline: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Enterobacteriaceae / chloramphenicol: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Enterobacteriaceae / chloramphenicol: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Enterobacteriaceae / chloramphenicol: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Enterobacteriaceae / ciprofloxacin: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Enterobacteriaceae / ciprofloxacin: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Enterobacteriaceae / ciprofloxacin: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Enterobacteriaceae / co-trimoxazole: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Enterobacteriaceae / co-trimoxazole: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Enterobacteriaceae / co-trimoxazole: 1/1 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Enterobacteriaceae / gentamicin: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Enterobacteriaceae / gentamicin: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Enterobacteriaceae / gentamicin: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Enterobacteriaceae / meropenem: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Enterobacteriaceae / meropenem: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Enterobacteriaceae / meropenem: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Enterobacteriaceae / amikacin: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Enterobacteriaceae / amikacin: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Enterobacteriaceae / amikacin: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Enterobacteriaceae / tigecycline: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Enterobacteriaceae / tigecycline: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Enterobacteriaceae / tigecycline: 0/1 (0.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / clindamycin: 3/3 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / clindamycin: 3/3 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / clindamycin: 3/3 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / erythromycin: 3/3 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / erythromycin: 3/3 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / erythromycin: 3/3 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / gentamicin: 3/3 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / gentamicin: 3/3 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / gentamicin: 3/3 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / cefoxitin: 3/3 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / cefoxitin: 3/3 (100.0%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / cefoxitin: 3/3 (100.0%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ofloxacin: 0/48 (0.0%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ofloxacin: 0/48 (0.0%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ofloxacin: 0/48 (0.0%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / oxacillin: 48/48 (100.0%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / oxacillin: 48/48 (100.0%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / oxacillin: 48/48 (100.0%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / gentamicin: 6/48 (12.5%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / gentamicin: 6/48 (12.5%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / gentamicin: 6/48 (12.5%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / ofloxacin: 0/39 (0.0%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / ofloxacin: 0/39 (0.0%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,specimen_site,AMR prevalence for Pseudomonas aeruginosa / ofloxacin: 0/39 (0.0%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / gentamicin: 10/39 (25.64%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / gentamicin: 10/39 (25.64%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,specimen_site,AMR prevalence for Pseudomonas aeruginosa / gentamicin: 10/39 (25.64%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella pneumoniae / ofloxacin: 0/22 (0.0%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella pneumoniae / ofloxacin: 0/22 (0.0%),,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella pneumoniae / ofloxacin: 0/22 (0.0%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,pathogen_specific,AMR prevalence for Proteus spp. / ampicillin: 21/28 (75.0%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Proteus spp. / ampicillin: 21/28 (75.0%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,specimen_site,AMR prevalence for Proteus spp. / ampicillin: 21/28 (75.0%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,pathogen_specific,AMR prevalence for Proteus spp. / cefazolin: 23/28 (82.14%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Proteus spp. / cefazolin: 23/28 (82.14%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,specimen_site,AMR prevalence for Proteus spp. / cefazolin: 23/28 (82.14%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / ampicillin: 24/26 (92.31%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / ampicillin: 24/26 (92.31%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella spp. / ampicillin: 24/26 (92.31%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ampicillin: 13/19 (68.42%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ampicillin: 13/19 (68.42%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ampicillin: 13/19 (68.42%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / penicillin: 22/22 (100.0%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / penicillin: 22/22 (100.0%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / penicillin: 22/22 (100.0%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / cefoxitin: 6/22 (27.27%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / cefoxitin: 6/22 (27.27%),,,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / cefoxitin: 6/22 (27.27%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ceftriaxone: 43/45 (95.56%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ceftriaxone: 43/45 (95.56%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ceftriaxone: 43/45 (95.56%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / gentamicin: 22/40 (55.0%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / gentamicin: 22/40 (55.0%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / gentamicin: 22/40 (55.0%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,pathogen_specific,AMR prevalence for Acinetobacter spp. / gentamicin: 32/39 (82.05%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Acinetobacter spp. / gentamicin: 32/39 (82.05%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,specimen_site,AMR prevalence for Acinetobacter spp. / gentamicin: 32/39 (82.05%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / ceftriaxone: 30/32 (93.75%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / ceftriaxone: 30/32 (93.75%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella spp. / ceftriaxone: 30/32 (93.75%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / gentamicin: 11/24 (45.83%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / gentamicin: 11/24 (45.83%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,specimen_site,AMR prevalence for Pseudomonas aeruginosa / gentamicin: 11/24 (45.83%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,pathogen_specific,AMR prevalence for Enterococcus spp. / vancomycin: 17/20 (85.0%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Enterococcus spp. / vancomycin: 17/20 (85.0%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,specimen_site,AMR prevalence for Enterococcus spp. / vancomycin: 17/20 (85.0%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / methicillin: 4/19 (21.05%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / methicillin: 4/19 (21.05%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / methicillin: 4/19 (21.05%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ampicillin: 13/13 (100.0%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ampicillin: 13/13 (100.0%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ampicillin: 13/13 (100.0%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ampicillin: 13/13 (100.0%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / amoxicillin-clavulanate: 12/13 (92.31%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / amoxicillin-clavulanate: 12/13 (92.31%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / amoxicillin-clavulanate: 12/13 (92.31%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / amoxicillin-clavulanate: 12/13 (92.31%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ceftriaxone: 12/13 (92.31%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ceftriaxone: 12/13 (92.31%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ceftriaxone: 12/13 (92.31%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ceftriaxone: 12/13 (92.31%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / penicillin: 15/18 (83.33%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / penicillin: 15/18 (83.33%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / penicillin: 15/18 (83.33%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / penicillin: 15/18 (83.33%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella pneumoniae / ampicillin: 16/16 (100.0%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella pneumoniae / ampicillin: 16/16 (100.0%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Klebsiella pneumoniae / ampicillin: 16/16 (100.0%),,,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,specimen_site,AMR prevalence for Klebsiella pneumoniae / ampicillin: 16/16 (100.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / gentamicin: 4/40 (10.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / gentamicin: 4/40 (10.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / gentamicin: 4/40 (10.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / vancomycin: 0/40 (0.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / vancomycin: 0/40 (0.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / vancomycin: 0/40 (0.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella spp. / gentamicin: 8/29 (27.59%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella spp. / gentamicin: 8/29 (27.59%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,specimen_site,AMR prevalence for Klebsiella spp. / gentamicin: 8/29 (27.59%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / gentamicin: 0/11 (0.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / gentamicin: 0/11 (0.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,specimen_site,AMR prevalence for Pseudomonas aeruginosa / gentamicin: 0/11 (0.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,pathogen_specific,AMR prevalence for Coagulase-negative staphylococci / vancomycin: 0/18 (0.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Coagulase-negative staphylococci / vancomycin: 0/18 (0.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,specimen_site,AMR prevalence for Coagulase-negative staphylococci / vancomycin: 0/18 (0.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,pathogen_specific,AMR prevalence for Gram-negative bacteria (aggregate) / gentamicin: 11/65 (16.92%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Gram-negative bacteria (aggregate) / gentamicin: 11/65 (16.92%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,specimen_site,AMR prevalence for Gram-negative bacteria (aggregate) / gentamicin: 11/65 (16.92%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,pathogen_specific,AMR prevalence for Gram-positive bacteria (aggregate) / vancomycin: 0/58 (0.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Gram-positive bacteria (aggregate) / vancomycin: 0/58 (0.0%),,,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,specimen_site,AMR prevalence for Gram-positive bacteria (aggregate) / vancomycin: 0/58 (0.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / penicillin: 3/5 (60.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / penicillin: 3/5 (60.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / penicillin: 3/5 (60.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / erythromycin: 4/5 (80.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / erythromycin: 4/5 (80.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / erythromycin: 4/5 (80.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / clindamycin: 4/5 (80.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / clindamycin: 4/5 (80.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / clindamycin: 4/5 (80.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / meropenem: 0/9 (0.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / meropenem: 0/9 (0.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / meropenem: 0/9 (0.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Pseudomonas aeruginosa / ceftriaxone: 8/8 (100.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Pseudomonas aeruginosa / ceftriaxone: 8/8 (100.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,specimen_site,AMR prevalence for Pseudomonas aeruginosa / ceftriaxone: 8/8 (100.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,pathogen_specific,AMR prevalence for Proteus spp. / ceftriaxone: 6/6 (100.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Proteus spp. / ceftriaxone: 6/6 (100.0%),,,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,specimen_site,AMR prevalence for Proteus spp. / ceftriaxone: 6/6 (100.0%),,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / oxacillin: 34/43 (79.07%),,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / oxacillin: 34/43 (79.07%),,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / oxacillin: 34/43 (79.07%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / cefepime: 26/29 (89.66%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / cefepime: 26/29 (89.66%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / cefepime: 26/29 (89.66%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / cefepime: 26/29 (89.66%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella pneumoniae / cefepime: 14/14 (100.0%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella pneumoniae / cefepime: 14/14 (100.0%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Klebsiella pneumoniae / cefepime: 14/14 (100.0%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella pneumoniae / cefepime: 14/14 (100.0%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / meropenem: 4/29 (13.79%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / meropenem: 4/29 (13.79%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / meropenem: 4/29 (13.79%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / meropenem: 4/29 (13.79%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella pneumoniae / meropenem: 9/14 (64.29%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella pneumoniae / meropenem: 9/14 (64.29%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Klebsiella pneumoniae / meropenem: 9/14 (64.29%),,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella pneumoniae / meropenem: 9/14 (64.29%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 12/17 (70.59%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 12/17 (70.59%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ciprofloxacin: 12/17 (70.59%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / vancomycin: 0/17 (0.0%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / vancomycin: 0/17 (0.0%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / vancomycin: 0/17 (0.0%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / clindamycin: 0/17 (0.0%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / clindamycin: 0/17 (0.0%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / clindamycin: 0/17 (0.0%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / gentamicin: 10/17 (58.82%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / gentamicin: 10/17 (58.82%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / gentamicin: 10/17 (58.82%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / co-trimoxazole: 15/17 (88.24%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / co-trimoxazole: 15/17 (88.24%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / co-trimoxazole: 15/17 (88.24%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / chloramphenicol: 15/17 (88.24%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / chloramphenicol: 15/17 (88.24%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / chloramphenicol: 15/17 (88.24%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / erythromycin: 15/17 (88.24%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / erythromycin: 15/17 (88.24%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / erythromycin: 15/17 (88.24%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / oxacillin: 17/54 (31.48%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / oxacillin: 17/54 (31.48%),,,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / oxacillin: 17/54 (31.48%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / cloxacillin: 0/14 (0.0%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / cloxacillin: 0/14 (0.0%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / cloxacillin: 0/14 (0.0%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ampicillin: 13/14 (92.86%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ampicillin: 13/14 (92.86%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ampicillin: 13/14 (92.86%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ampicillin: 13/14 (92.86%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ceftriaxone: 5/14 (35.71%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ceftriaxone: 5/14 (35.71%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ceftriaxone: 5/14 (35.71%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ceftriaxone: 5/14 (35.71%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella pneumoniae / ceftriaxone: 3/6 (50.0%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella pneumoniae / ceftriaxone: 3/6 (50.0%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Klebsiella pneumoniae / ceftriaxone: 3/6 (50.0%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella pneumoniae / ceftriaxone: 3/6 (50.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ceftriaxone: 3/3 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ceftriaxone: 3/3 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ceftriaxone: 3/3 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella pneumoniae / ceftriaxone: 8/8 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella pneumoniae / ceftriaxone: 8/8 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella pneumoniae / ceftriaxone: 8/8 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,pathogen_specific,AMR prevalence for Proteus spp. / ceftriaxone: 7/8 (87.5%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Proteus spp. / ceftriaxone: 7/8 (87.5%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,specimen_site,AMR prevalence for Proteus spp. / ceftriaxone: 7/8 (87.5%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,pathogen_specific,AMR prevalence for Enterobacter cloacae complex / ceftriaxone: 8/8 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Enterobacter cloacae complex / ceftriaxone: 8/8 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,specimen_site,AMR prevalence for Enterobacter cloacae complex / ceftriaxone: 8/8 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,pathogen_specific,AMR prevalence for Acinetobacter baumannii complex / ceftriaxone: 9/9 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Acinetobacter baumannii complex / ceftriaxone: 9/9 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,specimen_site,AMR prevalence for Acinetobacter baumannii complex / ceftriaxone: 9/9 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / cefoxitin: 2/2 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / cefoxitin: 2/2 (100.0%),,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / cefoxitin: 2/2 (100.0%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella species / ceftriaxone: 43/44 (97.73%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella species / ceftriaxone: 43/44 (97.73%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella species / ceftriaxone: 43/44 (97.73%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,pathogen_specific,AMR prevalence for Klebsiella species / ceftazidime: 40/44 (90.91%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Klebsiella species / ceftazidime: 40/44 (90.91%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,specimen_site,AMR prevalence for Klebsiella species / ceftazidime: 40/44 (90.91%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ceftriaxone: 11/11 (100.0%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ceftriaxone: 11/11 (100.0%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ceftriaxone: 11/11 (100.0%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ceftazidime: 11/11 (100.0%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ceftazidime: 11/11 (100.0%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ceftazidime: 11/11 (100.0%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / methicillin: 31/34 (91.18%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / methicillin: 31/34 (91.18%),,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / methicillin: 31/34 (91.18%),,,,,
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,pathogen_specific,AMR prevalence for Acinetobacter baumannii / ceftriaxone: 41/43 (95.35%),,,,,
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Acinetobacter baumannii / ceftriaxone: 41/43 (95.35%),,,,,
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,specimen_site,AMR prevalence for Acinetobacter baumannii / ceftriaxone: 41/43 (95.35%),,,,,
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,pathogen_specific,AMR prevalence for Acinetobacter baumannii / ceftazidime: 41/43 (95.35%),,,,,
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Acinetobacter baumannii / ceftazidime: 41/43 (95.35%),,,,,
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,specimen_site,AMR prevalence for Acinetobacter baumannii / ceftazidime: 41/43 (95.35%),,,,,
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,pathogen_specific,AMR prevalence for Acinetobacter baumannii / imipenem: 37/43 (86.05%),,,,,
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Acinetobacter baumannii / imipenem: 37/43 (86.05%),,,,,
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,specimen_site,AMR prevalence for Acinetobacter baumannii / imipenem: 37/43 (86.05%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / penicillin: 138/153 (90.2%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / penicillin: 138/153 (90.2%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / penicillin: 138/153 (90.2%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / penicillin: 138/153 (90.2%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / ampicillin: 117/153 (76.47%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / ampicillin: 117/153 (76.47%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / ampicillin: 117/153 (76.47%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / ampicillin: 117/153 (76.47%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / vancomycin: 0/153 (0.0%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / vancomycin: 0/153 (0.0%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Staphylococcus aureus / vancomycin: 0/153 (0.0%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / vancomycin: 0/153 (0.0%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ampicillin: 96/102 (94.12%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ampicillin: 96/102 (94.12%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ampicillin: 96/102 (94.12%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ampicillin: 96/102 (94.12%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / ceftriaxone: 101/102 (99.02%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / ceftriaxone: 101/102 (99.02%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / ceftriaxone: 101/102 (99.02%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / ceftriaxone: 101/102 (99.02%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,pathogen_specific,AMR prevalence for Escherichia coli / imipenem: 12/102 (11.76%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Escherichia coli / imipenem: 12/102 (11.76%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,mdr_xdr_pandr,AMR prevalence for Escherichia coli / imipenem: 12/102 (11.76%),,,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,specimen_site,AMR prevalence for Escherichia coli / imipenem: 12/102 (11.76%),,,,,
Worku2023-Ethiopia-FourHospitals-2020-2021-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / cefoxitin: 40/163 (24.54%),,,,,
Worku2023-Ethiopia-FourHospitals-2020-2021-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / cefoxitin: 40/163 (24.54%),,,,,
Worku2023-Ethiopia-FourHospitals-2020-2021-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / cefoxitin: 40/163 (24.54%),,,,,
Worku2023-Ethiopia-FourHospitals-2020-2021-1,amr_prevalence,pathogen_specific,AMR prevalence for Staphylococcus aureus / vancomycin: 1/40 (2.5%),,,,,
Worku2023-Ethiopia-FourHospitals-2020-2021-1,amr_prevalence,antibiotic_class_trends,AMR prevalence for Staphylococcus aureus / vancomycin: 1/40 (2.5%),,,,,
Worku2023-Ethiopia-FourHospitals-2020-2021-1,amr_prevalence,specimen_site,AMR prevalence for Staphylococcus aureus / vancomycin: 1/40 (2.5%),,,,,
Varghese2024-Multicountry-FALCON-2018-2020-01,outcomes_clinical,mortality,Mortality: 29/1161 (2.5%),,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,outcomes_clinical,mortality,Mortality: 1/124 (0.81%),,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,outcomes_clinical,mortality,Mortality: 3/294 (1.02%),,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,outcomes_clinical,mortality,Mortality: 4/36 (11.11%),,,,,
Varghese2024-Multicountry-FALCON-2018-2020-01,outcomes_clinical,readmissions,Readmissions: 136/1137 in 30 days (11.96%),,,,,
Kachipedzu2024-Malawi-QECH-2023-1,outcomes_clinical,readmissions,Readmissions: 12/20 in 30 days (60.0%),,,,,
Ali2023-Ethiopia-DessieHospital-2016-01,outcomes_clinical,prolonged_los,Length of stay: 35.25 days,,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,outcomes_clinical,prolonged_los,Length of stay: 2.0 days,,,,,
Kefale2020-Ethiopia-FinoteSelam-2019-2020-1,outcomes_clinical,prolonged_los,Length of stay: nan days,,,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,outcomes_clinical,prolonged_los,Length of stay: nan days,,,,,
Mukagendaneza2019-Rwanda-KigaliCHUK-2017_2018-01,outcomes_clinical,prolonged_los,Length of stay: nan days,,,,,
DeNardo2016-Tanzania-Dodoma-2013-1,outcomes_clinical,prolonged_los,Length of stay: 2.0 days,,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,outcomes_clinical,prolonged_los,Length of stay: nan days,,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,outcomes_clinical,prolonged_los,Length of stay: 4.4 days,,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,outcomes_clinical,prolonged_los,Length of stay: nan days,,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,economic_impact,direct_costs,Costs (direct_medical): 1500.0 EUR,,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,economic_impact,direct_costs,Costs (direct_medical): 3.0 EUR,,,,,
